<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1888-7546</journal-id>
<journal-title><![CDATA[Revista Andaluza de Medicina del Deporte]]></journal-title>
<abbrev-journal-title><![CDATA[Rev Andal Med Deporte]]></abbrev-journal-title>
<issn>1888-7546</issn>
<publisher>
<publisher-name><![CDATA[Centro Andaluz de Medicina del Deporte]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1888-75462014000400006</article-id>
<article-id pub-id-type="doi">10.1016/j.ramd.2014.03.001</article-id>
<title-group>
<article-title xml:lang="pt"><![CDATA[Influência da administração de eritropoietina humana recombinante sobre o desempenho físico: estudo de revisão]]></article-title>
<article-title xml:lang="es"><![CDATA[Influencia de administración de eritropoyetina humana recombinante en el rendimiento físico: un estudio de revisión]]></article-title>
<article-title xml:lang="en"><![CDATA[Effects of administration of human recombinant erythropoietin on physical performance: study review]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Caetano Júnior]]></surname>
<given-names><![CDATA[P.C.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[T.S.]]></given-names>
</name>
<xref ref-type="aff" rid="A02"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Lemes]]></surname>
<given-names><![CDATA[L.C.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[S.R.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Ribeiro]]></surname>
<given-names><![CDATA[W.]]></given-names>
</name>
<xref ref-type="aff" rid="A01"/>
</contrib>
</contrib-group>
<aff id="A01">
<institution><![CDATA[,Universidade do Vale do Paraíba (UNIVAP) Universidade do Vale do Paraíba (UNIVAP) Laboratório de Fisiologia e Farmacologia]]></institution>
<addr-line><![CDATA[São José dos Campos São Paulo]]></addr-line>
<country>Brasil</country>
</aff>
<aff id="A02">
<institution><![CDATA[,Universidade Federal de São Paulo (UNIFESP) Instituto de Ciência e Tecnologia ]]></institution>
<addr-line><![CDATA[São José dos Campos São Paulo]]></addr-line>
<country>Brasil</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>12</month>
<year>2014</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>12</month>
<year>2014</year>
</pub-date>
<volume>7</volume>
<numero>4</numero>
<fpage>170</fpage>
<lpage>177</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_arttext&amp;pid=S1888-75462014000400006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_abstract&amp;pid=S1888-75462014000400006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.isciii.es/scielo.php?script=sci_pdf&amp;pid=S1888-75462014000400006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="pt"><p><![CDATA[Objetivo: Discutir os resultados acerca dos efeitos do uso da eritropoietina humana recombinante (rHuEPO) sobre o desempenho físico, bem como relatar os efeitos adversos decorrentes desta prática, correlacionando os achados de estudos experimentais e clínicos. Métodos: Foram selecionados artigos científicos publicados nas bases de dados PubMed e SciELO, no período de 1985-2013, utilizando as seguintes palavras-chaves: eritropoietina/erythropoietin, desempenho atlético/athletic performance, resistência física/physical endurance, efeitos adversos/adverse effects e doping nos esportes/doping in sports. Resultados: Todos os estudos (n = 10) encontraram melhora nas variáveis de consumo máximo de oxigênio (VO2máx) e tempo de exaustão em humanos, utilizando diferentes protocolos de dosagens, que podem variar de 50-60 UI/kg nas primeiras semanas, com redução ao longo do tratamento. Dentre as reações adversas mais frequentes estão os acidentes trombovasculares, deficiência de ferro e hipertensão arterial sistêmica. Conclusão: O tratamento com rHuEPO em diferentes doses e períodos pode potencializar o desempenho físico de humanos, em virtude dos diferentes efeitos gerados, incluindo aumento no transporte de O2, redução das concentrações de lactato sanguíneo, aumento das concentrações de ácidos graxos livres no sangue e do glicogênio muscular.]]></p></abstract>
<abstract abstract-type="short" xml:lang="es"><p><![CDATA[Objetivo: Discutir los resultados relativos a los efectos del uso de la eritropoyetina humana recombinante (rHuEPO), sobre el rendimiento físico, así como los efectos adversos de su uso, así como la relación de los resultados de estudios experimentales y clínicos. Métodos: Se seleccionaron los artículos científicos publicados en revistas incluidas en PubMed y SciELO, en el período de 1985-2013, usando las siguientes palabras clave: eritropoietina/erythropoietin, desempenho atlético/athletic performance, resistência física/physical endurance, efeitos adversos/adverse effects e doping nos esportes/doping in sports. Resultados: Todos los artículos (n = 10), en relación con la influencia del tratamiento con rHuEPO en el rendimiento deportivo, mostraron una mejoría en las variables de consumo máximo de oxígeno (VO2máx) y el tiempo hasta el agotamiento en seres humanos, utilizando diferentes protocolos de dosis, que oscilan desde 50-60 UI/kg en las primeras semanas con reducción progresiva durante el tratamiento. Entre los efectos adversos más frecuentes se encuentran los accidentes vasculares trombóticos, la ferropenia y la hipertensión arterial. Conclusión: El tratamiento con dosis de rHuEPO y en diferentes períodos puede mejorar el rendimiento físico en los seres humanos, debido a los diferentes efectos generados, incluyendo el aumento del transporte de O2, la reducción de las concentraciones de lactato en sangre, aumento de las concentraciones de ácidos grasos libres en la sangre y glucógeno muscular.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Objective: Discuss the influence of rHuEPO on physical performance, as well as the adverse effects of this practice, exposing results from experimental and clinical studies. Methods: Were selected articles published in the basis, PubMed and SciELO databases, in the period 1985-2013, using the following keywords eritropoetina/erythropoietin, desempenho atlético/athletic performance, resistência física/physical endurance, efeitos adversos/adverse effects e doping nos esportes/doping in sports. Results: All articles (n = 10) related to the influence of treatment with rHuEPO on sports performance, found improvement in the variables of maximal oxygen uptake (VO2max) and time to exhaustion in humans, using different protocols dosages between 50 to 60 IU/kg during the first weeks with reduced throughout treatment. Among the most common adverse effects are the thrombovascular accidents, iron deficiency and hypertension. Conclusion: Treatment with rHuEPO doses and at different periods, can enhance physical performance in humans, because of the different generated effects, including increased O2 transport, reduction of blood lactate concentrations, increased concentrations of free fatty acids in the blood and muscle glycogen.]]></p></abstract>
<kwd-group>
<kwd lng="pt"><![CDATA[Eritropoietina]]></kwd>
<kwd lng="pt"><![CDATA[Desempenho atlético]]></kwd>
<kwd lng="pt"><![CDATA[Resistência física]]></kwd>
<kwd lng="pt"><![CDATA[Efeitos adversos]]></kwd>
<kwd lng="pt"><![CDATA[Doping nos esportes]]></kwd>
<kwd lng="es"><![CDATA[Eritropoyetina]]></kwd>
<kwd lng="es"><![CDATA[Rendimiento atlético]]></kwd>
<kwd lng="es"><![CDATA[Resistencia física]]></kwd>
<kwd lng="es"><![CDATA[Efectos adversos]]></kwd>
<kwd lng="es"><![CDATA[Doping deportivo]]></kwd>
<kwd lng="en"><![CDATA[Erythropoietin]]></kwd>
<kwd lng="en"><![CDATA[Athletic performance]]></kwd>
<kwd lng="en"><![CDATA[Physical endurance]]></kwd>
<kwd lng="en"><![CDATA[Adverse effects]]></kwd>
<kwd lng="en"><![CDATA[Doping in sports]]></kwd>
</kwd-group>
</article-meta>
</front><body><![CDATA[ <p><a name="top"></a><font face="Verdana" size="2"><b>ARTIGO DE REVIS&#195;O</b></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="4"><b>Influ&#234;ncia da administraç&#227;o de eritropoietina humana recombinante sobre o desempenho f&iacute;sico: estudo de revis&#227;o</b></font></p>     <p><font face="Verdana" size="4"><b>Influencia de administraci&oacute;n de eritropoyetina humana recombinante en el rendimiento f&iacute;sico: un estudio de revisi&oacute;n</b></font></p>     <p><font face="Verdana" size="4"><b>Effects of administration of human recombinant erythropoietin on physical performance: Study review</b></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>P.C. Caetano J&uacute;nior<sup>a</sup>, T.S. Cunha<sup>b</sup>, L.C. Lemes<sup>a</sup>, S.R. Ribeiro<sup>a</sup> e W. Ribeiro<sup>a</sup></b></font></p>     <p><font face="Verdana" size="2"><sup>a</sup> Laborat&oacute;rio de Fisiologia e Farmacologia, Instituto de Pesquisa e Desenvolvimento (IP&amp;D), Universidade do Vale do Para&iacute;ba (UNIVAP), S&#227;o Jos&eacute; dos Campos, S&#227;o Paulo, Brasil    <br><sup>b</sup> Instituto de Ci&#234;ncia e Tecnologia, Universidade Federal de S&#227;o Paulo (UNIFESP), S&#227;o Jos&eacute; dos Campos, S&#227;o Paulo, Brasil</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><a href="#bajo">Correspond&#234;ncia</a></font></p>     <p>&nbsp;</p>     <p>&nbsp;</p> <hr size="1">    <p><font face="Verdana" size="2"><b>RESUMO</b></font></p>     <p><font face="Verdana" size="2"><b>Objetivo:</b> Discutir os resultados acerca dos efeitos do uso da eritropoietina humana recombinante (rHuEPO) sobre o desempenho f&iacute;sico, bem como relatar os efeitos adversos decorrentes desta pr&aacute;tica, correlacionando os achados de estudos experimentais e cl&iacute;nicos.    <br><b>M&eacute;todos:</b> Foram selecionados artigos cient&iacute;ficos publicados nas bases de dados PubMed e SciELO, no per&iacute;odo de 1985-2013, utilizando as seguintes palavras-chaves: eritropoietina/<i>erythropoietin</i>, desempenho atl&eacute;tico/<i>athletic performance</i>, resist&#234;ncia f&iacute;sica/<i>physical endurance</i>, efeitos adversos/<i>adverse effects</i> e <i>doping</i> nos esportes/<i>doping in sports</i>.    <br><b>Resultados:</b> Todos os estudos (n = 10) encontraram melhora nas vari&aacute;veis de consumo m&aacute;ximo de oxig&#234;nio (VO<sub>2m&aacute;x</sub>) e tempo de exaust&#227;o em humanos, utilizando diferentes protocolos de dosagens, que podem variar de 50-60 UI/kg nas primeiras semanas, com reduç&#227;o ao longo do tratamento. Dentre as reaç&#245;es adversas mais frequentes est&#227;o os acidentes trombovasculares, defici&#234;ncia de ferro e hipertens&#227;o arterial sist&#234;mica.    <br><b>Conclus&#227;o:</b> O tratamento com rHuEPO em diferentes doses e per&iacute;odos pode potencializar o desempenho f&iacute;sico de humanos, em virtude dos diferentes efeitos gerados, incluindo aumento no transporte de O<sub>2</sub>, reduç&#227;o das concentraç&#245;es de lactato sangu&iacute;neo, aumento das concentraç&#245;es de &aacute;cidos graxos livres no sangue e do glicog&#234;nio muscular.</font></p>     <p><font face="Verdana" size="2"><b>Palavras chave:</b> Eritropoietina. Desempenho atl&eacute;tico. Resist&#234;ncia f&iacute;sica. Efeitos adversos. <i>Doping</i> nos esportes.</font></p> <hr size="1">    <p><font face="Verdana" size="2"><b>RESUMEN</b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><b>Objetivo:</b> Discutir los resultados relativos a los efectos del uso de la eritropoyetina humana recombinante (rHuEPO), sobre el rendimiento f&iacute;sico, as&iacute; como los efectos adversos de su uso, as&iacute; como la relaci&oacute;n de los resultados de estudios experimentales y cl&iacute;nicos.    <br><b>M&eacute;todos:</b> Se seleccionaron los art&iacute;culos cient&iacute;ficos publicados en revistas incluidas en PubMed y SciELO, en el per&iacute;odo de 1985-2013, usando las siguientes palabras clave: eritropoietina/<i>erythropoietin</i>, desempenho atl&eacute;tico/<i>athletic performance</i>, resist&#234;ncia f&iacute;sica/<i>physical endurance</i>, efeitos adversos/<i>adverse effects</i> e <i>doping</i> nos esportes/<i>doping in sports</i>.    <br><b>Resultados:</b> Todos los art&iacute;culos (n = 10), en relaci&oacute;n con la influencia del tratamiento con rHuEPO en el rendimiento deportivo, mostraron una mejor&iacute;a en las variables de consumo m&aacute;ximo de ox&iacute;geno (VO<sub>2m&aacute;x</sub>) y el tiempo hasta el agotamiento en seres humanos, utilizando diferentes protocolos de dosis, que oscilan desde 50-60 UI/kg en las primeras semanas con reducci&oacute;n progresiva durante el tratamiento. Entre los efectos adversos m&aacute;s frecuentes se encuentran los accidentes vasculares tromb&oacute;ticos, la ferropenia y la hipertensi&oacute;n arterial.    <br><b>Conclusi&oacute;n:</b> El tratamiento con dosis de rHuEPO y en diferentes per&iacute;odos puede mejorar el rendimiento f&iacute;sico en los seres humanos, debido a los diferentes efectos generados, incluyendo el aumento del transporte de O<sub>2</sub>, la reducci&oacute;n de las concentraciones de lactato en sangre, aumento de las concentraciones de &aacute;cidos grasos libres en la sangre y gluc&oacute;geno muscular.</font></p>     <p><font face="Verdana" size="2"><b>Palabras clave:</b> Eritropoyetina. Rendimiento atl&eacute;tico. Resistencia f&iacute;sica. Efectos adversos. Doping deportivo.</font></p> <hr size="1">    <p><font face="Verdana" size="2"><b>ABSTRACT</b></font></p>     <p><font face="Verdana" size="2"><b>Objective:</b> Discuss the influence of rHuEPO on physical performance, as well as the adverse effects of this practice, exposing results from experimental and clinical studies.    <br><b>Methods:</b> Were selected articles published in the basis, PubMed and SciELO databases, in the period 1985-2013, using the following keywords eritropoetina/<i>erythropoietin</i>, desempenho atl&eacute;tico/<i>athletic performance</i>, resist&#234;ncia f&iacute;sica/<i>physical endurance</i>, efeitos adversos/<i>adverse effects</i> e <i>doping</i> nos esportes/<i>doping in sports</i>.    <br><b>Results:</b> All articles (n = 10) related to the influence of treatment with rHuEPO on sports performance, found improvement in the variables of maximal oxygen uptake (VO<sub>2max</sub>) and time to exhaustion in humans, using different protocols dosages between 50 to 60 IU/kg during the first weeks with reduced throughout treatment. Among the most common adverse effects are the thrombovascular accidents, iron deficiency and hypertension.    <br><b>Conclusion:</b> Treatment with rHuEPO doses and at different periods, can enhance physical performance in humans, because of the different generated effects, including increased O<sub>2</sub> transport, reduction of blood lactate concentrations, increased concentrations of free fatty acids in the blood and muscle glycogen.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><b>Key words:</b> Erythropoietin. Athletic performance. Physical endurance. Adverse effects. Doping in sports.</font></p> <hr size="1">     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Introduç&#227;o</b></font></p>     <p><font face="Verdana" size="2">A eritropoietina humana recombinante (rHuEPO) &eacute; uma glicoprote&iacute;na altamente purificada, composta por uma sequ&#234;ncia de amino&aacute;cidos id&#234;ntica &agrave; da eritropoietina (EPO) end&oacute;gena<sup>1</sup>. Esta subst&#226;ncia tornou-se comercialmente dispon&iacute;vel a partir de 1988<sup>2</sup> e o tratamento com a rHuEPO contribuiu para minimizar o n&uacute;mero de transfus&#245;es de sangue de pacientes com anemia<sup>3</sup>.</font></p>     <p><font face="Verdana" size="2">Em virtude da dificuldade de detecç&#227;o e diferenciaç&#227;o entre a rHuEPO e a EPO end&oacute;gena, bem como do uso da t&eacute;cnica natural de hip&oacute;xia (HIF) intermitente, que desencadeia aumento da produç&#227;o de EPO no organismo<sup>4</sup>, a rHuEPO passou a ser utilizada de forma indiscriminada por atletas<sup>5</sup> com o objetivo de melhorar o desempenho f&iacute;sico, embora o uso indiscriminado tenha sido oficialmente proibido pelo Comit&#234; Ol&iacute;mpico Internacional (COI) em 1990<sup>6</sup>.</font></p>     <p><font face="Verdana" size="2">A literatura reporta que a administraç&#227;o subcut&#226;nea de rHuEPO, em diferentes doses, pode aumentar o VO<sub>2m&aacute;x</sub> e tempo de exaust&#227;o de humanos<sup>7-9</sup> e alterar as concentraç&#245;es de lactato sangu&iacute;neo<sup>10-12</sup>. Al&eacute;m disso, j&aacute; foi descrita a presença de receptores de EPO (rEPO) em vasos sangu&iacute;neos, na musculatura esquel&eacute;tica, em test&iacute;culos e em algumas linhagens celulares neopl&aacute;sicas, o que sugere a sua potencialidade tamb&eacute;m como alvo terap&#234;utico<sup>13-15</sup> e foi demonstrado que o tratamento com o horm&ocirc;nio recombinante pode provocar efeitos neurais, potencializando o desempenho sem alterar a produç&#227;o de eritr&oacute;citos<sup>16</sup>.</font></p>     <p><font face="Verdana" size="2">No entanto, os efeitos desencadeados por este horm&ocirc;nio n&#227;o se restringem ao desempenho f&iacute;sico e, neste sentido, j&aacute; foi demonstrado que a administraç&#227;o de rHuEPO pode causar aumento excessivo do hemat&oacute;crito e da viscosidade sangu&iacute;nea, reduzindo o d&eacute;bito card&iacute;aco<sup>18,19</sup>. Por este motivo, sabe-se que as reaç&#245;es adversas mais frequentes relacionadas ao tratamento com rHuEPO s&#227;o hipertens&#227;o arterial sist&#234;mica e acidente trombovascular<sup>20</sup>.</font></p>     <p><font face="Verdana" size="2">Com base no pressuposto, a presente revis&#227;o objetivou discutir os resultados acerca dos efeitos do uso da rHuEPO sobre o desempenho f&iacute;sico, abordando, inclusive, as alteraç&#245;es fisiol&oacute;gicas pouco discutidas na literatura, que v&#227;o al&eacute;m dos cl&aacute;ssicos relacionados a eritropoiese e que tamb&eacute;m ajudam a explicar o aumento do rendimento atl&eacute;tico. Al&eacute;m disso, visando alertar e conscientizar atletas e profissionais do meio esportivo sobre os riscos causados pelo uso de rHuEPO, o estudo buscou relatar os principais efeitos adversos decorrentes desta pr&aacute;tica, correlacionando os achados de estudos cl&iacute;nicos e experimentais.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>M&eacute;todos</b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">O presente trabalho de revis&#227;o sistem&aacute;tica utilizou as bases de dados PubMed e SciELO para selecionar os artigos cient&iacute;ficos de interesse, no per&iacute;odo de 1985-2013. As palavras-chave para seleç&#227;o dos estudos foram pesquisadas, tanto em l&iacute;ngua portuguesa, quanto em l&iacute;ngua inglesa, como segue: eritropoietina/<i>erythropoietin</i>, desempenho atl&eacute;tico/<i>athletic performance</i>, resist&#234;ncia f&iacute;sica/<i>physical endurance</i>, efeitos adversos/<i>adverse effects</i> e <i>doping</i> nos esportes/<i>doping in sports</i>.</font></p>     <p><font face="Verdana" size="2">No total encontraram-se 1.083 estudos, no entanto, ap&oacute;s os crit&eacute;rios de exclus&#227;o e inclus&#227;o chegou-se a 76 refer&#234;ncias. Os crit&eacute;rios de exclus&#227;o adotados foram de artigos cient&iacute;ficos relacionados somente ao uso terap&#234;utico da rHuEPO, n&#227;o apresentando, portanto, nenhum efeito relacionado a capacidade f&iacute;sica e/ou adverso do horm&ocirc;nio recombinante. Os crit&eacute;rios de inclus&#227;o foram de estudos contendo vari&aacute;veis relacionadas ao desempenho atl&eacute;tico e de efeitos adversos em humanos e animais, tratados com rHuEPO.</font></p>     <p><font face="Verdana" size="2"><i>Eritropoietina: estrutura, s&iacute;ntese e funç&#227;o</i></font></p>     <p><font face="Verdana" size="2">A EPO &eacute; composta por 165 amino&aacute;cidos com peso molecular em torno de 30 <i>Kilodalton</i> (kDa). &Eacute; formada em sua maioria (40%) por carboidratos e 2-4 cadeias sialiladas podem estar presentes em sua estrutura<sup>21-23</sup>. A fim de evitar que esta seja depurada pelo f&iacute;gado antes de alcançar o alvo fisiol&oacute;gico, os res&iacute;duos de &aacute;cido si&aacute;lico constituem um sinalizador biol&oacute;gico da EPO<sup>24</sup>.</font></p>     <p><font face="Verdana" size="2">Este horm&ocirc;nio &eacute; sintetizado nos rins (90% da produç&#227;o) e no f&iacute;gado (10%)<sup>20</sup>, com meia vida de aproximadamente 8 horas<sup>22</sup>, quando liberada, liga-se aos seus receptores (rEPO) na superf&iacute;cie dos precursores das c&eacute;lulas vermelhas (BFU-e, CFU-e, eritroblastos) localizados na medula &oacute;ssea. Essa glicoprote&iacute;na, al&eacute;m de prolongar a sobreviv&#234;ncia dessas c&eacute;lulas, tamb&eacute;m inibe a apoptose das c&eacute;lulas precursoras induzindo a proliferaç&#227;o e diferenciaç&#227;o das mesmas<sup>25-27</sup>.</font></p>     <p><font face="Verdana" size="2">A transcriç&#227;o da EPO &eacute; potencializada por meio da ativaç&#227;o do fator de transcriç&#227;o induz&iacute;vel por HIF. A subunidade HIF-1&alpha; quando inibida, pode associar-se &agrave; subunidade HIF-1&beta; formando um heterod&iacute;mero que se desloca para o n&uacute;cleo da c&eacute;lula, com o intuito de ativar a transcriç&#227;o do gene. No entanto, este mecanismo n&#227;o &eacute; somente ativado frente &agrave; HIF, mas tamb&eacute;m por outros est&iacute;mulos que incluem a hipoglicemia, o aumento de c&aacute;lcio intracelular, bem como a liberaç&#227;o de insulina, estrog&#234;nios, esteroides anab&oacute;licos e de v&aacute;rias citocinas como as interleucinas 1 e 6, capazes de aumentar a concentraç&#227;o de EPO e a express&#227;o dos rEPO, a fim de desencadear efeitos biol&oacute;gicos em c&eacute;lulas hematopoi&eacute;ticas<sup>28-30</sup>.</font></p>     <p><font face="Verdana" size="2">A express&#227;o do rEPO tamb&eacute;m &eacute; descrita em c&eacute;lulas vasculares, musculares lisas, mioblastos, test&iacute;culos e em linhagens de c&eacute;lulas tumorais<sup>14,15</sup>, por&eacute;m com efeitos diferentes daqueles desencadeados no tecido hematopoi&eacute;tico. O aumento da express&#227;o de rEPO nas c&eacute;lulas musculares est&aacute; associada &agrave; induç&#227;o de proliferaç&#227;o celular, e no sistema nervoso central, a EPO produzida por astr&oacute;ctitos, desempenha papel importante na resposta &agrave;s les&#245;es neuronais<sup>27,30</sup>.</font></p>     <p><font face="Verdana" size="2">Os rEPO fazem parte da classe de receptores ligados &agrave;s citocinas tipo I, onde a ligaç&#227;o do horm&ocirc;nio a eles resulta em dimerizaç&#227;o e ativaç&#227;o de diferentes cascatas de sinalizaç&#227;o intracelular<sup>27</sup>. A ativaç&#227;o do receptor ligado &agrave; janus tirosina quinase 2 (<i>Janus tyrosine kinase</i> - JAK2), respons&aacute;vel por propagar o sinal, ativar&aacute; o sinal secund&aacute;rio de transduç&#227;o de mol&eacute;culas, incluindo os transdutores e ativadores da transcriç&#227;o 5 (<i>Signal transducer and activator of transcription</i> - STAT5), prote&iacute;nas quinase mit&oacute;geno ativadas (<i>Mitogen activated protein kinase</i> - MAPK) e fosfatidilinositol-3-quinase (<i>Phosphatidylinositol-3-kinase</i> - PI3K)<sup>25,27,31</sup>.</font></p>     <p><font face="Verdana" size="2">A ativaç&#227;o da JAK2 induz a fosforilaç&#227;o da tirosina e dimerizaç&#227;o de STAT. Este mecanismo de aç&#227;o, envolvendo a transduç&#227;o de sinal por vias como JAK2/STAT5 do sistema de prote&iacute;na G (RAS), canal de c&aacute;lcio e quinases (<a href="#f1">fig. 1</a>) &eacute; respons&aacute;vel pelos efeitos da EPO sobre a eritropoiese, diferenciaç&#227;o, proliferaç&#227;o e sobreviv&#234;ncia celular, bem como pela ativaç&#227;o de mecanismos antiapopt&oacute;ticos<sup>25,31</sup>.</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p align="center"><a name="f1"><img src="/img/revistas/ramd/v7n4/revision2_f1.jpg"></a></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2">A EPO tem a capacidade inerente de estimular a produç&#227;o de hem&aacute;cias e de hemoglobina, aumentando consequentemente a oxigenaç&#227;o tecidual<sup>23</sup>, principalmente em situaç&#245;es de HIF e mediante ao treinamento f&iacute;sico em grandes altitudes<sup>32</sup>.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Eritropoietina humana recombinante</b></font></p>     <p><font face="Verdana" size="2">Em 1988 a rHuEPO tornou-se comercialmente dispon&iacute;vel, ap&oacute;s evid&#234;ncias de que ela poderia minimizar a necessidade da transfus&#227;o de sangue e ainda melhorar o bem estar de pacientes an&#234;micos com doença renal cr&ocirc;nica<sup>2,33</sup>. A sua identificaç&#227;o foi poss&iacute;vel atrav&eacute;s do uso da tecnologia do ADN recombinante e hoje sabe-se que o gene da EPO humana situa-se no cromossomo 7q11-22, constitu&iacute;do por 5 &eacute;xons e 4 &iacute;ntrons, respons&aacute;vel pela s&iacute;ntese de polipept&iacute;dio p&oacute;s-transcricional contendo 193 amino&aacute;cidos<sup>34</sup>.</font></p>     <p><font face="Verdana" size="2">Durante a modificaç&#227;o p&oacute;s-traducional, a glicosilaç&#227;o ocorre com a adiç&#227;o de 3 N-ligados (em Asn-24, Asn-38 e Asn-83) e uma O-ligados (Ser-126) oligossac&aacute;ridos &aacute;cidas, a formaç&#227;o de 2 ligaç&#245;es dissulfureto em Cys-7 para Cys-161 e em Cys-29 para Cys-33, concomitante a remoç&#227;o de 27 amino&aacute;cidos. Acredita-se que a Arg-166 no COOH terminal &eacute; clivada antes da liberaç&#227;o da EPO na circulaç&#227;o, com a estrutura prim&aacute;ria de um EPO madura e, portanto, rHuEPO, contendo 165 amino&aacute;cidos<sup>35</sup>.</font></p>     <p><font face="Verdana" size="2">Existem algumas formas comerciais de rHuEPO dispon&iacute;veis no mercado para uso terap&#234;utico, tais como, epoetina alfa, epoetina beta e epoetina &ocirc;mega. O m&eacute;todo de s&iacute;ntese determina a classificaç&#227;o das mesmas e enquanto as epoetinas alfa e beta s&#227;o sintetizadas a partir de c&eacute;lulas ovarianas de hamster chin&#234;s, a epoetina &ocirc;mega &eacute; produzida em c&eacute;lulas renais de filhote de hamster<sup>36,37</sup>.</font></p>     <p><font face="Verdana" size="2">A administraç&#227;o da rHuEPO pode ser feita pelas vias subcut&#226;nea (SC), intravenosa (IV) e intraperitoneal (IP). A via SC apresenta diversas vantagens sobre a via IV, principalmente por ser desnecess&aacute;rio o estabelecimento do acesso venoso para administraç&#227;o e reduç&#227;o de at&eacute; 30% da dose semanal em pacientes sob hemodi&aacute;lise<sup>38</sup>.</font></p>     <p>&nbsp;</p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2"><b><i>Doping</i> e eritropoetina humana recombinante</b></font></p>     <p><font face="Verdana" size="2">Ap&oacute;s os Jogos Ol&iacute;mpicos de Inverno de Calgary e Jogos Ol&iacute;mpicos de Seul, esportistas de modalidades em que prepondera o metabolismo aer&oacute;bio, como ciclismo, esqui de fundo, maratona, tri&aacute;tlon, entre outros, passaram a utilizar abusivamente a rHuEPO, visando a melhora do desempenho atl&eacute;tico6<sup>10,39,40</sup>. Esta pr&aacute;tica sem supervis&#227;o m&eacute;dica foi oficialmente proibida pelo COI em 1990<sup>6</sup>.</font></p>     <p><font face="Verdana" size="2">A detecç&#227;o da rHuEPO tem sido realizada por m&eacute;todos diretos, que identificam subst&#226;ncias ex&oacute;genas com base nas suas propriedades f&iacute;sico-qu&iacute;micas, ou m&eacute;todos moleculares que reconhecem transgenes de EPO diretos e indiretos, baseando-se nos biomarcadores hematol&oacute;gicos<sup>41,42</sup>. No entanto, alguns fatores limitam a investigaç&#227;o precisa da rHuEPO, como por exemplo, an&aacute;logos deste horm&ocirc;nio, <i>doping</i> gen&eacute;tico<sup>42</sup> e diferenciaç&#227;o entre rHuEPO e EPO end&oacute;gena, devido &agrave; sua complexidade estrutural, presença de baixas concentraç&#245;es nos fluidos biol&oacute;gicos e estrutura qu&iacute;mica bastante semelhante a de sua forma end&oacute;gena<sup>5</sup>. Lunby et al.<sup>43</sup> ainda ressaltam que inicialmente a rHuEPO pode ser detectada, mas que ap&oacute;s o per&iacute;odo de administraç&#227;o esta detecç&#227;o torna-se dificultada.</font></p>     <p><font face="Verdana" size="2">O pr&oacute;ximo per&iacute;odo corresponde &agrave; volta da transfus&#227;o sangu&iacute;nea como alternativa indetect&aacute;vel para o <i>doping</i> envolvendo a rHuEPO, que foi consumada pela operaç&#227;o Puerto em 2006. Apesar da especificidade do teste de detecç&#227;o direta (<i>Isoelectric focusing test</i> - IEF), os laborat&oacute;rios observaram padr&#245;es irregulares do horm&ocirc;nio, identificados como urina ativa e urina de esforço. Al&eacute;m disto, no boletim oficial da auditoria, perfis indetect&aacute;veis de EPO foram relatados com o uso do IEF<sup>44</sup>. Por outro lado, casos positivos de biossimilares de EPO e ativadores cont&iacute;nuos de receptores de eritropoiese (<i>Continuous erythropoiesis receptor activator</i> - CERA) foram reportados em 2007<sup>45</sup>.</font></p>     <p><font face="Verdana" size="2">Em meados de 2010 e 2011 teve in&iacute;cio uma investigaç&#227;o relacionada &agrave; efici&#234;ncia da combinaç&#227;o de agentes qu&iacute;micos para estabilizaç&#227;o de perfis de esteroides end&oacute;genos e da gonadotrofina cori&ocirc;nica humana na urina, servindo para o controle de <i>doping</i>. Por&eacute;m, estudos adicionais ser&#227;o necess&aacute;rios para a validaç&#227;o do m&eacute;todo<sup>45</sup>. Em setembro de 2011 a WADA lançou o "passaporte biol&oacute;gico" que se refere a um mapeamento das vari&aacute;veis biol&oacute;gicas de atletas, visando detectar vari&aacute;veis fisiol&oacute;gicas anormais e o uso de subst&#226;ncias il&iacute;citas. No entanto, este sistema ainda n&#227;o foi validado<sup>46</sup>.</font></p>     <p><font face="Verdana" size="2">Embora a rHuEPO esteja dispon&iacute;vel no mercado h&aacute; mais de uma d&eacute;cada, o IEF proposto antes dos Jogos Ol&iacute;mpicos de Sydney veio substituir os testes secund&aacute;rios que eram utilizados. Esta metodologia permitiu identificar o primeiro caso positivo de uso da rHuEPO em 2001, seguido pela primeira detecç&#227;o oficial do uso do novo estimulador de prote&iacute;na da eritropoiese (<i>Novel erythropoiesis stimulating protein</i> - NESP), um ano depois<sup>24,45</sup>.</font></p>     <p><font face="Verdana" size="2">Diversos avanços relacionados &agrave; utilizaç&#227;o da t&eacute;cnica de focalizaç&#227;o isoel&eacute;trica para identificaç&#227;o da EPO permitem atualmente identificar diferenças sutis entre a glicosilaç&#227;o e sialilaç&#227;o, e desta forma possibilitam a diferenciaç&#227;o entre an&aacute;logos end&oacute;genos e a rHuEPO recombinante. Os estudos destacam que este m&eacute;todo foi internacionalmente aceite para a detecç&#227;o de estimuladores da eritropoiese (ESA), usando um anticorpo monoclonal antiEPO altamente sens&iacute;vel, o AE7A5<sup>34</sup>.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Efeitos da eritropoietina humana recombinante sobre o desempenho esportivo</b></font></p>     <p><font face="Verdana" size="2">J&aacute; est&aacute; bem estabelecido que o tratamento com a rHuEPO aumenta a s&eacute;rie vermelha sangu&iacute;nea<sup>37</sup>. Robach et al.<sup>47</sup> por exemplo, relataram aumento significativo da concentraç&#227;o de hemoglobina (Hb) e do hemat&oacute;crito em humanos, a partir do d&eacute;cimo dia de tratamento com rHuEPO, em resposta &agrave; administraç&#227;o di&aacute;ria de 65 UI/kg. Ashenden et al.<sup>48</sup> tamb&eacute;m relataram aumento desses 2 componentes, ap&oacute;s administraç&#227;o de rHuEPO em doses vari&aacute;veis, alterando a cada 4 semanas 10, 20, 30 UI/kg. Adultos saud&aacute;veis tratados em dias alternados, com 65 UI/kg de rHuEPO, por um per&iacute;odo de 16 dias, tamb&eacute;m apresentaram aumento significativo de hemoglobina e eritr&oacute;citos<sup>39</sup>. Da mesma forma, Lundby e Robach<sup>49</sup> encontraram aumento a partir da quinta semana de tratamento e Ninot, Connes, Caillaud<sup>50</sup> tamb&eacute;m encontraram aumento do hemat&oacute;crito e de Hb, em indiv&iacute;duos treinados durante 6 semanas (3 primeiras semanas - 50 UI/kg e nas 2 subsequentes - 20 UI/kg).</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Dentre os estudos envolvendo animais de experimentaç&#227;o, tamb&eacute;m foi encontrado aumento significativo de hemat&oacute;crito em ratos tratados com rHuEPO e submetidos ao treinamento aer&oacute;bio por 30 min com sobrecarga de 5% do peso corporal<sup>10</sup>. Da mesma forma, Verbrugge e Goodnough<sup>51</sup> observaram aumento da s&eacute;rie vermelha em ratos submetidos ao treinamento f&iacute;sico aer&oacute;bio com o aux&iacute;lio de rodas motorizadas e tratamento com rHuEPO.</font></p>     <p><font face="Verdana" size="2">Em relaç&#227;o aos efeitos deste horm&ocirc;nio recombinante sobre o desempenho esportivo &eacute; importante ressaltar que este &eacute; um fen&ocirc;meno que n&#227;o depende somente do aumento da s&eacute;rie vermelha do sangue, mas sim de uma combinaç&#227;o de diversos processos e fatores intr&iacute;nsecos e extr&iacute;nsecos<sup>52</sup>. Em modalidades esportivas aer&oacute;bias, tais como corrida de longa dist&#226;ncia, ciclismo ou esqui <i>cross country</i>, o principal fator que determina o desempenho f&iacute;sico &eacute; a efici&#234;ncia relacionada ao transporte e utilizaç&#227;o de O<sub>2</sub> pela musculatura esquel&eacute;tica (VO<sub>2m&aacute;x</sub>), durante o exerc&iacute;cio. Esta utilizaç&#227;o &eacute; dependente da concentraç&#227;o total de Hb, do d&eacute;bito card&iacute;aco e da diferença de O<sub>2</sub> arteriovenosa (<a href="#f2">fig. 2</a>)<sup>53</sup>.</font></p>     <p>&nbsp;</p>     <p align="center"><a name="f2"><img src="/img/revistas/ramd/v7n4/revision2_f2.jpg"></a></font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2">Foi demonstrado que a rHuEPO administrada em doses reduzidas durante 12 semanas (50 UI/kg durante as 3 primeiras semanas e 20 UI/kg nas 5 semanas subsequentes) foi suficiente para manter os eritr&oacute;citos e o VO<sub>2m&aacute;x</sub> em n&iacute;veis elevados de atletas amadores<sup>54</sup>. O aumento de hemat&oacute;crito, Hb e VO<sub>2m&aacute;x</sub> ap&oacute;s administraç&#227;o deste horm&ocirc;nio tamb&eacute;m foi observado por Lundby et al.<sup>55</sup>. Da mesma forma, Thomsen et al.<sup>56</sup>, ap&oacute;s avaliarem homens saud&aacute;veis tratados com rHuEPO (50 UI/kg), relataram, al&eacute;m do aumento de hemat&oacute;crito, Hb, VO<sub>2m&aacute;x</sub> (12 e 11,6% nas semanas 4 e 11, respectivamente) e aumento de 54% no tempo de exaust&#227;o. Al&eacute;m disto, Wilkerson et al.<sup>57</sup> encontraram em jovens, 4 semanas ap&oacute;s o tratamento com rHuEPO (150 UI/kg), aumentos significativos de Hb e VO<sub>2pico</sub>, sem efeito significativo sobre a cin&eacute;tica do VO<sub>2</sub>, quando comparado ao grupo controle.</font></p>     <p><font face="Verdana" size="2">Recentemente Durussel et al.<sup>58</sup> avaliaram os efeitos da rHuEPO (50 UI/kg) em homens treinados, por 4 semanas. Tanto o tempo no teste de 3.000 m (10:30 &plusmn; 1:07 min:seg vs. 11 min08 &plusmn; 1:15 min:seg), quanto o VO<sub>2m&aacute;x</sub> (56,0 &plusmn; 6,2 mL.min<sup>-1</sup>.kg<sup>-1</sup> vs. 60,7 &plusmn; 5,8 mL.min<sup>-1</sup>.kg<sup>-1</sup>) dos indiv&iacute;duos, foram significativamente melhorados ap&oacute;s a quarta semana de tratamento, bem como, permaneceram maximizados ap&oacute;s 4 semanas do t&eacute;rmino da administraç&#227;o, com 10:46 &plusmn; 1:13 min:seg e 58,0 &plusmn; 5,6 mL.min<sup>-1</sup>.kg<sup>-1</sup>, respectivamente.</font></p>     <p><font face="Verdana" size="2">Dos 10 artigos envolvendo VO<sub>2m&aacute;x</sub> e tempo de exaust&#227;o de humanos tratados com rHuEPO, todos relataram melhoria destas vari&aacute;veis (<a target="_blank" href="/img/revistas/ramd/v7n4/revision2_t1.jpg">tabela 1</a>). Estes resultados indicam que o tratamento com rHuEPO, com doses e per&iacute;odos diferenciados, podem potencializar a condiç&#227;o aer&oacute;bia de indiv&iacute;duos treinados e/ou de atletas. A principal explicaç&#227;o para isso se d&aacute; pela capacidade aumentada de transportar O<sub>2</sub> no sangue, no entanto, como j&aacute; apresentado, a capacidade aer&oacute;bia depende de v&aacute;rios outros fatores<sup>53,56</sup>.</font></p>     <p><font face="Verdana" size="2">Com isso, o presente trabalho de revis&#227;o, buscou outras explicaç&#245;es para a melhora do rendimento esportivo, decorrente dos efeitos da rHuEPO. Um relato interessante foi de que indiv&iacute;duos treinados aerobicamente s&#227;o altamente sens&iacute;veis aos efeitos da rHuEPO em sua aptid&#227;o f&iacute;sica, e ainda, que este horm&ocirc;nio pode at&eacute; mesmo, alterar par&#226;metros emocionais e comportamentais, relacionados ao prazer, autoestima e aumento da libido<sup>50</sup>.</font></p>     <p><font face="Verdana" size="2">Outros achados tamb&eacute;m ajudaram a esclarecer os efeitos deste horm&ocirc;nio recombinante sobre o rendimento f&iacute;sico. Estudos demonstraram que a rHuEPO pode tamb&eacute;m influenciar o metabolismo anaer&oacute;bio, atrav&eacute;s da avaliaç&#227;o do lactato sangu&iacute;neo<sup>10-12</sup>, substrato determinante do limiar anaer&oacute;bio, considerado um importante biomarcador para prescriç&#227;o e monitoramento do treinamento<sup>59,60</sup>. Foi observado aumento no transporte de lactato, mediado por transportadores monocarboxilato 1 e 4 em eritr&oacute;citos, ap&oacute;s tratamento com rHuEPO em seres humanos<sup>11</sup>, assim como menores concentraç&#245;es de lactato em resposta a exerc&iacute;cios com intensidades variando de 60-100% do VO<sub>2m&aacute;x</sub>, em atletas, ap&oacute;s 8 semanas de tratamento com rHuEPO<sup>54</sup>.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Lavoie et al.<sup>10</sup> encontraram em animais tratados com rHuEPO, ap&oacute;s 30 min de nataç&#227;o com sobrecarga adicional de 5% do peso corporal, maiores concentraç&#245;es de &aacute;cidos graxos livres no sangue e de glicog&#234;nio muscular, com menores concentraç&#245;es de lactato sangu&iacute;neo. Estes resultados evidenciam que a utilizaç&#227;o do substrato energ&eacute;tico durante o exerc&iacute;cio &eacute; afetada pela maior disponibilidade de oxig&#234;nio e menor produç&#227;o energ&eacute;tica pelo metabolismo anaer&oacute;bio.</font></p>     <p><font face="Verdana" size="2">Al&eacute;m destes efeitos, Cayla et al.<sup>61</sup> observaram que ratos treinados e tratados com rHuEPO apresentam aumento das atividades espec&iacute;ficas de enzimas oxidativas, citocromo C oxidase e L-3-hidroxiacil-CoA desidrogenase e fosfofrutoquinase, no musculoesquel&eacute;tico. Estes achados sugerem que a administraç&#227;o de rHuEPO possa levar ao aumento da resist&#234;ncia muscular esquel&eacute;tica e oxigenaç&#227;o de todos os tecidos. Lundby et al.<sup>13</sup>, por sua vez, observaram que os rEPO est&#227;o presentes na vasculatura e fibra muscular esquel&eacute;tica e ainda que uma &uacute;nica injeç&#227;o de rHuEPO (200 UI/kg) &eacute; capaz de reduzir a express&#227;o de RNA mensageiro (RNAm) de mioglobina, de receptores de transferrina e de rHuEPO.</font></p>     <p><font face="Verdana" size="2">H&aacute; evid&#234;ncias de que a rHuEPO, quando administrada em altas doses, pode atravessar a barreira hemato-encef&aacute;lica, contribuindo para reduç&#227;o da fadiga central e melhora da cogniç&#227;o, de modo a aumentar a capacidade de exerc&iacute;cio independente da eritropoiese. Entretanto, o rendimento f&iacute;sico e cognitivo dos indiv&iacute;duos n&#227;o foi alterado, sugerindo que o efeito ergog&#234;nico se d&#234; exclusivamente por meio do aumento da capacidade em transportar O<sub>2</sub> no sangue<sup>62</sup>. Em contrapartida, Schuler et al.<sup>16</sup> destacam que o tratamento com rHuEPO pode provocar efeitos neurais, potencializando o desempenho f&iacute;sico, sem necessariamente alterar a produç&#227;o de c&eacute;lulas vermelhas do sangue.</font></p>     <p><font face="Verdana" size="2">Estudos recentes v&#234;m demonstrando que a rHuEPO tamb&eacute;m pode ajudar no tratamento do diabetes e da obesidade<sup>63</sup>. Foi observada reduç&#227;o da glicemia em ratos tratados com rHuEPO, em virtude, principalmente, de um aumento da atividade do transportador de glicose 4 (GLUT4)<sup>64</sup>. Mikol&aacute;s et al.<sup>64</sup> observaram tamb&eacute;m perda de peso em animais tratados com rHuEPO. Al&eacute;m disto, Christensen et al.<sup>65</sup>, ap&oacute;s investigarem os efeitos da administraç&#227;o aguda de rHuEPO sobre o metabolismo da sensibilidade &agrave; insulina em indiv&iacute;duos jovens saud&aacute;veis, observaram aumento do gasto energ&eacute;tico em resposta &agrave; administraç&#227;o de uma &uacute;nica dose do horm&ocirc;nio (400 UI/kg). Adicionalmente, j&aacute; foi relatado que a rHuEPO est&aacute; relacionada com a prevenç&#227;o de les&#227;o renal aguda, em um modelo experimental de treinamento f&iacute;sico de alta intensidade, em virtude de seu efeito antiapopt&oacute;tico<sup>66</sup>.</font></p>     <p><font face="Verdana" size="2">Apesar de grande parte dos estudos mostrar a importante influ&#234;ncia da rHuEPO sobre diversos par&#226;metros fisiol&oacute;gicos, alguns trabalhos relataram a inexist&#234;ncia dos efeitos do horm&ocirc;nio sobre vari&aacute;veis que poderiam maximizar o desempenho f&iacute;sico.</font></p>     <p><font face="Verdana" size="2">Um estudo que examinou diversos registros de ciclistas em per&iacute;odos rotulados de epidemia da rHuEPO, encontrou resultados de desempenho normalmente distribu&iacute;dos e linearmente relacionados, quando comparados a per&iacute;odos n&#227;o epid&#234;micos. Apesar dos resultados n&#227;o serem conclusivos, devido &agrave; falta de vari&aacute;veis biol&oacute;gicas dos atletas analisados, os autores relataram que os efeitos da rHuEPO sobre os resultados de ciclistas profissionais podem ser superestimados<sup>67</sup>.</font></p>     <p><font face="Verdana" size="2">De acordo com Juel et al.<sup>68</sup>, o uso prolongado de rHuEPO n&#227;o pode explicar o aumento do desempenho, corroborando com um &uacute;nico estudo que n&#227;o observou efeito significativo sobre a velocidade m&aacute;xima aer&oacute;bia em ratos, ap&oacute;s administraç&#227;o de rHuEPO por 3 semanas<sup>69</sup>. Acredita-se que o per&iacute;odo de tratamento deste estudo tenha sido insuficiente para alterar a condiç&#227;o aer&oacute;bia dos animais, uma vez que grande parte dos estudos encontrados observou os efeitos do horm&ocirc;nio, a partir da quarta semana de tratamento (<a target="_blank" href="/img/revistas/ramd/v7n4/revision2_t1.jpg">tabela 1</a>).</font></p>     <p><font face="Verdana" size="2">Por fim, vale ressaltar que o tratamento com rHuEPO parece n&#227;o influenciar os efeitos relacionados a adaptaç&#245;es musculares esquel&eacute;ticas, incluindo, hipertrofia, biog&#234;nese mitocondrial, miog&#234;nese e angiog&#234;nese em diferentes tipos de fibras musculares<sup>13,69</sup>.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Efeitos adversos decorrentes do uso indiscriminado da eritropoietina recombinante humana</b></font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Os riscos decorrentes da administraç&#227;o da rHuEPO j&aacute; foram relatados h&aacute; algumas d&eacute;cadas, como o caso de mortes durante repouso envolvendo ciclistas no in&iacute;cio dos anos 90 em competiç&#227;o na Europa<sup>6</sup>. Os atletas que abusam deste horm&ocirc;nio recombinante geralmente consideram apenas o benef&iacute;cio ao desempenho e ignoram os eventuais efeitos adversos acurto e longo prazo<sup>70,71</sup>. Por este motivo, alguns programas de conscientizaç&#227;o sobre os efeitos colaterais foram criados de modo a minimizar a utilizaç&#227;o indiscriminada deste horm&ocirc;nio no meio esportivo<sup>72</sup>.</font></p>     <p><font face="Verdana" size="2">Sabe-se que os atletas apresentam predisposiç&#227;o &agrave; hemoconcentraç&#227;o em virtude da desidrataç&#227;o que ocorre frequentemente ap&oacute;s o esforço f&iacute;sico. Com isso, a administraç&#227;o da rHuEPO potencializaria este efeito desencadeando aumento excessivo do hemat&oacute;crito, da viscosidade sangu&iacute;nea e reduç&#227;o do d&eacute;bito card&iacute;aco<sup>18,19</sup>. Al&eacute;m disto, estudos relataram que o tratamento com rHuEPO pode desencadear hipertens&#227;o em indiv&iacute;duos e em atletas, em virtude justamente do aumento da viscosidade sangu&iacute;nea<sup>55,62</sup> e ainda que as reaç&#245;es adversas mais frequentes relacionadas ao tratamento com rHuEPO s&#227;o os acidentes trombovasculares, defici&#234;ncia de ferro e hipertens&#227;o arterial sist&#234;mica<sup>20,73</sup>.</font></p>     <p><font face="Verdana" size="2">Meziri et al.<sup>74</sup> destacaram que a administraç&#227;o cr&ocirc;nica de rHuEPO pode gerar graves efeitos colaterais cardiovasculares e desta forma os autores estudaram a rHuEPO e sua associaç&#227;o com o &oacute;xido n&iacute;trico, supondo que este pode proteger os efeitos nocivos cardiovasculares, em ratos treinados. Os resultados mostraram que o exerc&iacute;cio impediu o aumento da press&#227;o arterial induzida por um inibidor da s&iacute;ntese de &oacute;xido n&iacute;trico (170 &plusmn; 5 mmHg) e que os animais treinados e tratados com rHuEPO e &oacute;xido n&iacute;trico desenvolveram hipertens&#227;o arterial grave (228 &plusmn; 9 mmHg), sugerindo que a utilizaç&#227;o de rHuEPO no esporte, a fim de melhorar o desempenho f&iacute;sico, representa um fator de risco elevado e fatal, especialmente com preexist&#234;ncia de risco cardiovascular.</font></p>     <p><font face="Verdana" size="2">No mesmo sentido, Piloto et al.<sup>71</sup>, ap&oacute;s avaliarem os efeitos da rHuEPO sobre alteraç&#245;es cardiovasculares em ratos submetidos ao exerc&iacute;cio aer&oacute;bio cr&ocirc;nico, relataram que o tratamento hormonal aumenta n&#227;o s&oacute; o n&uacute;mero de c&eacute;lulas vermelhas, mas tamb&eacute;m pode acarretar outras modificaç&#245;es cardiovasculares graves, tais como hipertrofia do mioc&aacute;rdio, hipertens&#227;o, hiperatividade simp&aacute;tica e serotonin&eacute;rgica.</font></p>     <p><font face="Verdana" size="2">Apesar dos efeitos colaterais decorrentes de seu uso indiscriminado, sabe-se que a administraç&#227;o de doses fisiol&oacute;gicas de rHuEPO &eacute; ben&eacute;fica no tratamento de diversas doenças. Neste sentido, j&aacute; foi demonstrado que a insufici&#234;ncia card&iacute;aca congestiva por anemia pode ser minimizada pelo tratamento da rHuEPO subcut&#226;nea e ferro endovenoso, melhorando assim a dispneia, fadiga, funç&#227;o card&iacute;aca, funç&#227;o renal e capacidade de exerc&iacute;cio, reduzindo a necessidade de hospitalizaç&#227;o e melhorando a qualidade de vida<sup>75,76</sup>.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Recomendaç&#245;es finais</b></font></p>     <p><font face="Verdana" size="2">Os estudos mostraram que o tratamento com rHuEPO, sob protocolos com diferentes dosagens e tempo, promove alteraç&#245;es da s&eacute;rie vermelha do sangue, aumentando os n&iacute;veis de eritr&oacute;citos e de Hb, tanto em humanos, quanto em animais.</font></p>     <p><font face="Verdana" size="2">Em relaç&#227;o aos efeitos deste horm&ocirc;nio recombinante sobre o desempenho atl&eacute;tico, todos os estudos (n = 10) encontraram aumento do VO<sub>2m&aacute;x</sub> e tempo de exaust&#227;o, em humanos, na quarta semana de tratamento. Interessantemente, um estudo com animais n&#227;o encontrou efeito significativo da capacidade aer&oacute;bia, utilizando apenas 3 semanas de administraç&#227;o. Assim, os achados indicam que o per&iacute;odo ideal para obter-se uma aç&#227;o representativa da rHuEPO sobre vari&aacute;veis do desempenho f&iacute;sico &eacute; de, no m&iacute;nimo, 4 semanas de tratamento.</font></p>     <p><font face="Verdana" size="2">Pelo fato dos estudos utilizarem diferentes protocolos de dosagens, o entendimento e a padronizaç&#227;o das doses, que supostamente potencializaria o desempenho atl&eacute;tico com maior efic&aacute;cia, foram dificultados. No entanto, observou-se que grande parte dos estudos utiliza de protocolos, incluindo doses de 50 e 60 UI/kg, nas primeiras semanas, com reduç&#227;o ao longo do tratamento.</font></p>     ]]></body>
<body><![CDATA[<p><font face="Verdana" size="2">Apesar dos estudos atribu&iacute;rem a melhora do desempenho em raz&#227;o da rHuEPO maximizar o transporte de O<sub>2</sub> no sangue, a presente revis&#227;o buscou apresentar outros efeitos da rHuEPO que ajudassem a explicar este fen&ocirc;meno, uma vez que este efeito, isoladamente, &eacute; insuficiente para explicar o rendimento atl&eacute;tico, que depende de v&aacute;rios outros fatores, incluindo principalmente tipo de treinamento f&iacute;sico e gen&eacute;tica.</font></p>     <p><font face="Verdana" size="2">Foi observado em diferentes estudos que al&eacute;m dos cl&aacute;ssicos relacionados &agrave; eritropoiese, o tratamento com o horm&ocirc;nio pode influenciar o metabolismo anaer&oacute;bio, reduzindo as concentraç&#245;es de lactato sangu&iacute;neo e ainda promover aumento das concentraç&#245;es de &aacute;cidos graxos livres no sangue, de glicog&#234;nio muscular e de atividades espec&iacute;ficas de enzimas oxidativas, citocromo C oxidase, L-3-hidroxiacil-CoA desidrogenase e fosfofrutoquinase no musculoesquel&eacute;tico.</font></p>     <p><font face="Verdana" size="2">Al&eacute;m disso, h&aacute; relatos de que indiv&iacute;duos treinados aerobicamente s&#227;o altamente sens&iacute;veis aos efeitos da rHuEPO, bem como que o tratamento com o horm&ocirc;nio pode desencadear alteraç&#245;es emocionais e comportamentais, relacionados ao prazer, autoestima e aumento da libido.</font></p>     <p><font face="Verdana" size="2">Os efeitos adversos apresentados pelos estudos apontam sobre os riscos do uso indiscriminado de rHuEPO. O aumento da viscosidade sangu&iacute;nea pode desencadear um quadro de acidentes trombovasculares em indiv&iacute;duos tratados com o horm&ocirc;nio, al&eacute;m de outras reaç&#245;es adversas que tamb&eacute;m podem ocorrer, tais como hipertens&#227;o arterial e defici&#234;ncia de ferro. Vale ressaltar que a rHuEPO em doses fisiol&oacute;gicas promove efeitos ben&eacute;ficos, podendo ser utilizado para o tratamento de diversas doenças, no entanto, esta pr&aacute;tica sem prescriç&#227;o m&eacute;dica &eacute; extremamente perigosa, al&eacute;m de ser considerada <i>doping</i> no &#226;mbito esportivo.</font></p>     <p><font face="Verdana" size="2">Por fim, vale ressaltar a import&#226;ncia de novos estudos envolvendo o tratamento com rHuEPO e diferentes protocolos de treinamento f&iacute;sico. Assim como novos esclarecimentos sobre os efeitos adversos, de modo a alertar e conscientizar atletas e indiv&iacute;duos, que pretendem fazer uso deste horm&ocirc;nio recombinante il&iacute;cito.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Conflito de interesses</b></font></p>     <p><font face="Verdana" size="2">Os autores declaram n&#227;o haver conflito de interesses.</font></p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><b>Refer&#234;ncias</b></font></p>     ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">1. Jacobs K, Shoemaker C, Rudersdorf R, Neill SD, Kaufman RJ, Mufson A, et al. Isolation and characterization of genomic and cDNA clones of human erythropoietin. Nature. 1985;313:6-10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474422&pid=S1888-7546201400040000600001&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">2. Choi D, Kim M, Park J. Erythropoietin: Physico and biochemical analysis. J Chromatogr B. 1996;687:189-99.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474424&pid=S1888-7546201400040000600002&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">3. Tanaka T, Nangaku M. Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents. Exp Cell Res. 2012;318:1068-73.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474426&pid=S1888-7546201400040000600003&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">4. Balestra C, Germonpré P. EPO and doping. Eur J Appl Physiol. 2010;109:1001-2.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474428&pid=S1888-7546201400040000600004&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">5. Gareau R, Brisson GR, Chénard C, Gagnon MG, Audran M. Total fibrin and fibrinogen degradation products in urine: A possible probe to detect illicit users of the physical-performance enhancer erythropoietin? Horm Res. 1995;44:189-92.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474430&pid=S1888-7546201400040000600005&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">6. River L, Saugy M. Peptides hormones abuse in sport: State of the art in the detection of growth hormone and erythropoietin. Toxin Rev. 1999;18:145-76.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474432&pid=S1888-7546201400040000600006&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">7. Audran M, Gareau R, Matecki S, Durand F, Chenard C, Sicart MT, et al. Effects of erythropoietin administration in training athletes and possible indirect detection in doping control. Med Sci Sports Exerc. 1999;31:639-45.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474434&pid=S1888-7546201400040000600007&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">8. Ekblom B, Berglund B. Effect of erythropoietin administration on maximal aerobic power in man. Scand J Med Sci Sports. 1991;2:88-93.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474436&pid=S1888-7546201400040000600008&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">9. Birkeland KI, Stray-Gundersen J, Hemmersbach P, Hallen J, Hug E, Bahr R. Effect of rhEPO administration on serum levels of sTfR and cycling performance. Med Sci Sports Exerc. 2000;7:1238-43.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474438&pid=S1888-7546201400040000600009&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">10. Lavoie C, Diguet A, Milot M, Gareau R. Erythropoietin (rHuEPO) doping: Effects of exercise on anaerobic metabolism in rats. Int J Sports Med. 1998;19:281-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474440&pid=S1888-7546201400040000600010&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">11. Connes P, Caillaud C, Mercier J, Bouix D, Casties JF. Injections of recombinant human erythropoietin increases lactate influx into erythrocytes. J Appl Physiol. 2004;97:326-32.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474442&pid=S1888-7546201400040000600011&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">12. Meierhenrich R, Jedicke H, Voigt A, Lange H. The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients. Clin Nephrol. 1996;45:90-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474444&pid=S1888-7546201400040000600012&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">13. Lundby C, Hellsten Y, Jensen MB, Munch AS, Pilegaard H. Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle. J Appl Physiol. 2008;104:1154-60.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474446&pid=S1888-7546201400040000600013&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">14. Lappin T. The cellular biology of erythropoietin receptors. Oncologist. 2003;8:15-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474448&pid=S1888-7546201400040000600014&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">15. Acs G, Xu X, Chu C, Acs P, Verma A. Prognostic significance of erythropoietin expression in human endometrial carcinoma. Cancer. 2004;100:2376-80.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474450&pid=S1888-7546201400040000600015&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">16. Schuler B, Vogel J, Grenacher B, Jacobs RA, Arras M, Gassmann M. Acute and chronic elevation of erythropoietin in the brain improves exercise performance in mice without inducing erythropoiesis. FASEB J. 2012;26(9):3884-90.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474452&pid=S1888-7546201400040000600016&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">17. Adamson JW. Regulation of red blood cell production. Am J Med. 1996;101:4-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474454&pid=S1888-7546201400040000600017&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">18. Aquino Neto FR. O papel do atleta na sociedade e o controle de dopagem no esporte. Rev Bras Med Esporte. 2001;7:1-11.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474456&pid=S1888-7546201400040000600018&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">19. Berardi D, Agati L. Cardiovascular adverse reactions after the administration of recombinant human erythropoietin: Light and shade. Minerva Cardioangiol. 2012;60:227-36.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474458&pid=S1888-7546201400040000600019&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">20. Garcia JMJ, Sánchez ET, Hidalgo DO, Conejo EA. Erytropoietin pharmacology. Clin Transl Oncol. 2007;9:715-22.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474460&pid=S1888-7546201400040000600020&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">21. Lohmeyer JA, Essmann E, Richerson SJ, Hagel C, Egana JT, Condurache A, et al. Use of erythropoietin as adjuvant therapy in nerve reconstruction. Langenbecks Arch Surg. 2008;393:317-23.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474462&pid=S1888-7546201400040000600021&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">22. Schmidt CA, Ramos AS, Silva JEP, Fronza M, Dalmora SL. Avaliação da atividade e caracterização de eritropoietina humana recombinante em produtos farmacêuticos. Arq Bras Endocrinol Metab. 2003;47(2):183-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474464&pid=S1888-7546201400040000600022&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">23. Bento RMA, Damasceno LMP, Neto FRA. Eritropoetina humana recombinante no esporte: uma revisão. Rev Bras Med Esporte. 2003;9(3):169-80.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474466&pid=S1888-7546201400040000600023&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">24. Bahlmann FH, Fliser D. Erythropoietin and renoprotection. Hypertension. 2009;18:15-20.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474468&pid=S1888-7546201400040000600024&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">25. Engert A. Recombinant human erythropoietin in oncology: Current statuts and further developments. Ann Oncol. 2005;16:1584-95.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474470&pid=S1888-7546201400040000600025&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">26. Hardee ME, Arcasoy MO, Blackwell KL, Kirkpatrick JP, Dewhirst MW. Erythropoietin biology in cancer. Clin Cancer Res. 2006;12(2):332-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474472&pid=S1888-7546201400040000600026&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">27. Hsieh MM, Linde NS, Wynter A, Metzger M, Wong C, Langsetmo I, et al. HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques. Blood. 2007;110:2140-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474474&pid=S1888-7546201400040000600027&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">28. Jelkmann W, Pagel H, Wolff M, Fandrey J. Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys. Life Sci. 1992;50:301-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474476&pid=S1888-7546201400040000600028&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">29. Tentori L, Graziani G. Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: Is there a cancer risk? Pharmacol Res. 2007;55:359-69.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474478&pid=S1888-7546201400040000600029&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">30. Ng T, Marx G, Littlewood T, Macdougall I. Recombinant erythropoietin in clinical practice. Postgrad Med J. 2003;79:367-76.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474480&pid=S1888-7546201400040000600030&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">31. Robach P, Schmitt EL, Brugniaux JV, Nicolet G, Duvallet A, Fouillot JP, et al. Living high-training low: Effect on erythropoiesis and maximal aerobic performance in elite Nordic skiers. Eur J Appl Physiol. 2006;97:695-705.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474482&pid=S1888-7546201400040000600031&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">32. Tsitsimpikou C, Kouretas D, Tsarouhas K, Fitch K, Spandidos DA, Tsatsakis A. Applications and biomonitoring issues of recombinant erythropoietins for doping control. Ther Drug Monit. 2011;33:3-13.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474484&pid=S1888-7546201400040000600032&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">33. Jelkmann W. Erythropoietin: Structure, control of production and function. Physiol Rev. 1992;72:449-89.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474486&pid=S1888-7546201400040000600033&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">34. Inoue N, Takeuchi M, Ohashi H, Suzuki T. The production of recombinant human erythropoietin. Biotechnol Annu Rev. 1995;1:297-313.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474488&pid=S1888-7546201400040000600034&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">35. Skibeli V, Nielsen-Lie G, Torjesen P. Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin. Blood. 2001;98:3626-34.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474490&pid=S1888-7546201400040000600035&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">36. Storring PL, Tiplady RJ, Gaines Das RE, Stenning BE, Lamikanra A, Rafferty B, et al. Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties. Br J Haematol. 1998;100:79-89.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474492&pid=S1888-7546201400040000600036&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">37. Macdougall IC. Meeting the challenges of a new millennium: Optimizing the use of recombinant human erythropoietin. Nephrol Dial Transplant. 1998;13: 23-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474494&pid=S1888-7546201400040000600037&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">38. Christensen B, Sackmann-Sala L, Cruz-Topete D, Jorgensen JO, Jessen N, Lundby C, et al. Novel serum biomarkers for erythropoietin use in humans: A proteomic approach. J Appl Physiol. 2011;110:149-56.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474496&pid=S1888-7546201400040000600038&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">39. Kohler M, Ayotte C, Desharnais P, Flenker U, Lüdke S, Thevis M, et al. Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels. Int J Sports Med. 2008;29:1-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474498&pid=S1888-7546201400040000600039&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">40. Abellan R, Ventura R, Pichini S, Palmi I, Bellver M, Olive R, et al. Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse. Int J Sports Med. 2007;28:9-15.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474500&pid=S1888-7546201400040000600040&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">41. Robinson N, Giraud S, Saudan C, Baume N, Avois L, Mangin P, et al. Erythropoietin and blood doping. Br J Sports Med. 2006;40:30-4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474502&pid=S1888-7546201400040000600041&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">42. Lundby C, Achman-Andersen NJ, Thomsen JJ, Norgaard AM, Robach P. Testing for recombinant human erythropoietin in urine: Problems associated with current anti-doping testing. J Appl Physiol. 2008;105:417-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474504&pid=S1888-7546201400040000600042&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">43. Lamon S, Robinson N, Saugy M. Procedures for monitoring recombinant erythropoietin and analogs in doping. Endocrinol Metab Clin N Am. 2010;39: 141-54.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474506&pid=S1888-7546201400040000600043&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">44. Tsivou M, Georgakopoulos DG, Dimopoulou HA, Koupparis MA, Atta-Politou J, Georgakopoulos CG. Stabilization of human urine abuse in sports: The antidoping perspective. Asian J Androl. 2008;10:391-402.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474508&pid=S1888-7546201400040000600044&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">45. John MJ, Jaison V, Jain K, Kakkar N, Jacob JJ. Erythropoietin use and abuse. Indian J Endocrinol Metab. 2012;16:220-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474510&pid=S1888-7546201400040000600045&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">46. Robach P, Recalcati S, Girelli D, Gelfi C, Aachmann-Andersen NJ, Thomsen JJ. Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin. Blood. 2009;113(26):6707-15.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474512&pid=S1888-7546201400040000600046&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">47. Ashenden M, Clare E, Gough CE, Garnham A, Gore CJ, Sharpe K. Current markers of the Athlete Blood Passport do not flag microdose EPO doping. Eur J Appl Physiol. 2011;111:2307-14.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474514&pid=S1888-7546201400040000600047&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">48. Lundby C, Robach P. Assessment of total haemoglobin mass: Can it detect erythropoietin-induced blood manipulations? Eur J Appl Physiol. 2010;108:197-200.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474516&pid=S1888-7546201400040000600048&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">49. Ninot G, Connes F, Caillaud C. Effects of recombinant human erythropoietin injections on physical self in endurance athletes. J Sports Sci. 2006;24:383-91.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474518&pid=S1888-7546201400040000600049&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">50. Verbrugge DJ, Goodnough LT. The effect of recombinant human erythropoietin treatment on the endurance performance of Sprague-Dawley rats. Scand J Clin Lab Invest. 1994;54:55-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474520&pid=S1888-7546201400040000600050&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">51. Kiss MAPDM, Böhme MTS, Mansoldo AC, Degaki E, Regazzini M. Desempenho e talento esportivos. Rev Paul Educ Fís. 2004;18:89-100.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474522&pid=S1888-7546201400040000600051&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">52. Jelkmann W, Lundby C. Blood doping and its detection. Blood. 2011;118(9):2395-404.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474524&pid=S1888-7546201400040000600052&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">53. Russell G, Gore CJ, Ashenden MJ, Parisotto R, Hahn AG. Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise. Eur J Appl Physiol. 2002;86:442-9.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474526&pid=S1888-7546201400040000600053&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">54. Lundby C, Robach P, Boushel R, Thomsen JJ, Rasmussen P, Koskolou M, et al. Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport? J Appl Physiol. 2008;105:581-7.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474528&pid=S1888-7546201400040000600054&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">55. Thomsen JJ, Rentsch RL, Robach P, Calbet JAL, Boushel R, Rasmussen P, et al. Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity. Eur J Appl Physiol. 2007;101:481-6.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474530&pid=S1888-7546201400040000600055&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">56. Wilkerson DP, Rittweger J, Berger NJ, Naish PF, Jones AM. Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans. J Physiol. 2005;15:639-52.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474532&pid=S1888-7546201400040000600056&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">57. Durussel J, Daskalaki E, Anderson M, Chatterji T, Wondimu DH, Padmanabhan N, et al. Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men. PLoS One. 2013;8(2):e56151.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474534&pid=S1888-7546201400040000600057&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">58. Zagatto AM, Papoti M, Caputo F, Mendes OC, Denadai BS, Baldissera V, et al. Comparação entre a utilização de saliva e sangue para determinação do lactato mínimo em cicloergômetro e ergômetro de braço em mesa-tenistas. Rev Bras Med Esporte. 2004;10:475-80.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474536&pid=S1888-7546201400040000600058&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">59. Freitas JS, Junior MAC, Franco FSC, Rezende LS, Santos AS, Maia HO, et al. Treinamento aeróbio em natação melhora a resposta de parâmetros metabólicos de ratos durante teste de esforço. Rev Bras Med Esporte. 2010;16(2):134-8.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474538&pid=S1888-7546201400040000600059&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">60. Cayla JL, Maire P, Duvallet A, Wahrmann JP. Erythropoietin induces a shift of muscle phenotype from fast glycolytic to slow oxidative. Int J Sports Med. 2008;296:460-5.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474540&pid=S1888-7546201400040000600060&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">61. Rasmussen P, Foged EM, Krogh-Madsen R, Nielsen J, Nielsen TR, Olsen NV, et al. Effects of erythropoietin administration on cerebral metabolism and exercise capacity in men. J Appl Physiol. 2010;109:476-83.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474542&pid=S1888-7546201400040000600061&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">62. Katz O, Stuible M, Golishevski N, Lifshitz L, Tremblay ML, Gassmann M, et al. Erythropoietin treatment leads to reduced blood glucose levels and body mass: Insights from murine models. J Endocrinol. 2010;205:87-95.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474544&pid=S1888-7546201400040000600062&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">63. Mikolás E, Cseh J, PAP M, Szijarto IA, Balogh A, Laczy B, et al. Effects of erythropoietin on glucose metabolism. Horm Metab Res. 2012;44:279-85.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474546&pid=S1888-7546201400040000600063&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">64. Christensen B, Vendelbo MH, Krusenstjerna-Hafstrom T, Madsen M, Pedersen SB, Jessen N, et al. Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men. J Appl Physiol. 2012;112:1114-21.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474548&pid=S1888-7546201400040000600064&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">65. Lin X, Qu S, Hu M, Jiang C. Protective effect of erythropoietin on renal injury induced by acute exhaustive exercise in the rat. Int J Sports Med. 2010;31:847-53.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474550&pid=S1888-7546201400040000600065&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">66. Lodewijkx HF, Brouwer B. Some empirical notes on the epo epidemic in professional cycling. Res Q Exerc Sport. 2011;82:740-54.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474552&pid=S1888-7546201400040000600066&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">67. Juel C, Thomsen JJ, Rentsch RL, Lundby C. Effects of prolonged recombinant human erythropoietin administration on muscle membrane transport systems and metabolic marker enzymes. Eur J Appl Physiol. 2007;102:41-4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474554&pid=S1888-7546201400040000600067&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">68. Martinez-Bello VE, Sanchis-Gomar F, Romagnoli M, Derbre F, Gomez-Cabrera MC, Vina J. Three weeks of erythropoietin treatment hampers skeletal muscle mitochondrial biogenesis in rats. J Physiol Biochem. 2012;68(4): 593-601.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474556&pid=S1888-7546201400040000600068&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">69. Eagleton HJ, Littlewood TJ. Update on the clinical use and misuse of erythropoietin. Curr Hematol Rep. 2003;2:109-15.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474558&pid=S1888-7546201400040000600069&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">70. Piloto N, Teixeira HM, Teixeira-Lemos E, Parada B, Garrido P, Sereno J, et al. Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic. Cardiovasc Toxicol. 2009;9:201-10.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474560&pid=S1888-7546201400040000600070&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    ]]></body>
<body><![CDATA[<!-- ref --><p><font face="Verdana" size="2">71. Cunha TS, Cunha NS, Moura MJCS, Marcondes FK. Esteróides anabólicos androgênicos e sua relação com a prática desportiva. Braz J Pharm Sci. 2004;40:165-79.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474562&pid=S1888-7546201400040000600071&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">72. Jones EH. Recombinant human erythropoietin. Am J Hosp Pharm. 1989;46:20-3.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474564&pid=S1888-7546201400040000600072&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">73. Meziri F, Binda D, Touati S, Pellegrin M, Berthelot A, Touyz RM, et al. Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin. Eur J Physiol. 2011;111:1929-38.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474566&pid=S1888-7546201400040000600073&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">74. Guglin ME, Koul D. Cardiovascular effects of erythropoietin: anemia and beyond. Cardiol Rev. 2006;14:200-4.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474568&pid=S1888-7546201400040000600074&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>    <!-- ref --><p><font face="Verdana" size="2">75. Manolis AS, Tzeis S, Triantafyllou K, Michaelidis J, Pyrros I, Sakellaris N, et al. Erythropoietin in heart failure and other cardiovascular diseases: Hematopoietic and pleiotropic effects. Curr Drug Targets Cardiovasc Haematol Disord. 2005;5:355-75.    &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[&#160;<a href="javascript:void(0);" onclick="javascript: window.open('/scielo.php?script=sci_nlinks&ref=4474570&pid=S1888-7546201400040000600075&lng=','','width=640,height=500,resizable=yes,scrollbars=1,menubar=yes,');">Links</a>&#160;]<!-- end-ref --></font></p>     ]]></body>
<body><![CDATA[<p>&nbsp;</p>     <p>&nbsp;</p>     <p><font face="Verdana" size="2"><a href="#top"><img border="0" src="/img/revistas/ramd/v7n4/seta.gif" width="15" height="17"></a><a name="bajo"></a><b>Correspond&#234;ncia:</b>    <br>Correio eletrónico: <a href="mailto:paulocaetanoj@hotmail.com">paulocaetanoj@hotmail.com</a>    <br>(P.C. Caetano Júnior)</font></p>     <p><font face="Verdana" size="2">Recebido a 4 de março de 2013    <br>Aceito a 17 de março de 2014</font></p>      ]]></body>
<back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Shoemaker]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Rudersdorf]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Neill]]></surname>
<given-names><![CDATA[SD]]></given-names>
</name>
<name>
<surname><![CDATA[Kaufman]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Mufson]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Isolation and characterization of genomic and cDNA clones of human erythropoietin]]></article-title>
<source><![CDATA[Nature]]></source>
<year>1985</year>
<volume>313</volume>
<page-range>6-10</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Choi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kim]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Park]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin: Physico and biochemical analysis]]></article-title>
<source><![CDATA[J Chromatogr B.]]></source>
<year>1996</year>
<volume>687</volume>
<page-range>189-99</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tanaka]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Nangaku]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recent advances and clinical application of erythropoietin and erythropoiesis-stimulating agents]]></article-title>
<source><![CDATA[Exp Cell Res.]]></source>
<year>2012</year>
<volume>318</volume>
<page-range>1068-73</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Balestra]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Germonpré]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[EPO and doping]]></article-title>
<source><![CDATA[Eur J Appl Physiol.]]></source>
<year>2010</year>
<volume>109</volume>
<page-range>1001-2</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Gareau]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Brisson]]></surname>
<given-names><![CDATA[GR]]></given-names>
</name>
<name>
<surname><![CDATA[Chénard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Gagnon]]></surname>
<given-names><![CDATA[MG]]></given-names>
</name>
<name>
<surname><![CDATA[Audran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Total fibrin and fibrinogen degradation products in urine: A possible probe to detect illicit users of the physical-performance enhancer erythropoietin?]]></article-title>
<source><![CDATA[Horm Res.]]></source>
<year>1995</year>
<volume>44</volume>
<page-range>189-92</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[River]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Saugy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Peptides hormones abuse in sport: State of the art in the detection of growth hormone and erythropoietin]]></article-title>
<source><![CDATA[Toxin Rev.]]></source>
<year>1999</year>
<volume>18</volume>
<page-range>145-76</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Audran]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gareau]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Matecki]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Durand]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Chenard]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Sicart]]></surname>
<given-names><![CDATA[MT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of erythropoietin administration in training athletes and possible indirect detection in doping control]]></article-title>
<source><![CDATA[Med Sci Sports Exerc.]]></source>
<year>1999</year>
<volume>31</volume>
<page-range>639-45</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ekblom]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Berglund]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of erythropoietin administration on maximal aerobic power in man]]></article-title>
<source><![CDATA[Scand J Med Sci Sports]]></source>
<year>1991</year>
<volume>2</volume>
<page-range>88-93</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Birkeland]]></surname>
<given-names><![CDATA[KI]]></given-names>
</name>
<name>
<surname><![CDATA[Stray-Gundersen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hemmersbach]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Hallen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Hug]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Bahr]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of rhEPO administration on serum levels of sTfR and cycling performance]]></article-title>
<source><![CDATA[Med Sci Sports Exerc.]]></source>
<year>2000</year>
<volume>7</volume>
<page-range>1238-43</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lavoie]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Diguet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Milot]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gareau]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin (rHuEPO) doping: Effects of exercise on anaerobic metabolism in rats]]></article-title>
<source><![CDATA[Int J Sports Med.]]></source>
<year>1998</year>
<volume>19</volume>
<page-range>281-6</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Connes]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Caillaud]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Mercier]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Bouix]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Casties]]></surname>
<given-names><![CDATA[JF]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Injections of recombinant human erythropoietin increases lactate influx into erythrocytes]]></article-title>
<source><![CDATA[J Appl Physiol.]]></source>
<year>2004</year>
<volume>97</volume>
<page-range>326-32</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meierhenrich]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jedicke]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Voigt]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lange]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effect of erythropoietin on lactate, pyruvate and excess lactate under physical exercise in dialysis patients]]></article-title>
<source><![CDATA[Clin Nephrol.]]></source>
<year>1996</year>
<volume>45</volume>
<page-range>90-7</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lundby]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Hellsten]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Jensen]]></surname>
<given-names><![CDATA[MB]]></given-names>
</name>
<name>
<surname><![CDATA[Munch]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Pilegaard]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin receptor in human skeletal muscle and the effects of acute and long-term injections with recombinant human erythropoietin on the skeletal muscle]]></article-title>
<source><![CDATA[J Appl Physiol.]]></source>
<year>2008</year>
<volume>104</volume>
<page-range>1154-60</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lappin]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The cellular biology of erythropoietin receptors]]></article-title>
<source><![CDATA[Oncologist]]></source>
<year>2003</year>
<volume>8</volume>
<page-range>15-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Acs]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Xu]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Acs]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Verma]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prognostic significance of erythropoietin expression in human endometrial carcinoma]]></article-title>
<source><![CDATA[Cancer]]></source>
<year>2004</year>
<volume>100</volume>
<page-range>2376-80</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schuler]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vogel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Grenacher]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Jacobs]]></surname>
<given-names><![CDATA[RA]]></given-names>
</name>
<name>
<surname><![CDATA[Arras]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Gassmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Acute and chronic elevation of erythropoietin in the brain improves exercise performance in mice without inducing erythropoiesis]]></article-title>
<source><![CDATA[FASEB J.]]></source>
<year>2012</year>
<volume>26</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>3884-90</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Adamson]]></surname>
<given-names><![CDATA[JW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Regulation of red blood cell production]]></article-title>
<source><![CDATA[Am J Med.]]></source>
<year>1996</year>
<volume>101</volume>
<page-range>4-6</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Aquino Neto]]></surname>
<given-names><![CDATA[FR]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[O papel do atleta na sociedade e o controle de dopagem no esporte]]></article-title>
<source><![CDATA[Rev Bras Med Esporte]]></source>
<year>2001</year>
<volume>7</volume>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Berardi]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Agati]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cardiovascular adverse reactions after the administration of recombinant human erythropoietin: Light and shade]]></article-title>
<source><![CDATA[Minerva Cardioangiol.]]></source>
<year>2012</year>
<volume>60</volume>
<page-range>227-36</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Garcia]]></surname>
<given-names><![CDATA[JMJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sánchez]]></surname>
<given-names><![CDATA[ET]]></given-names>
</name>
<name>
<surname><![CDATA[Hidalgo]]></surname>
<given-names><![CDATA[DO]]></given-names>
</name>
<name>
<surname><![CDATA[Conejo]]></surname>
<given-names><![CDATA[EA]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erytropoietin pharmacology]]></article-title>
<source><![CDATA[Clin Transl Oncol.]]></source>
<year>2007</year>
<volume>9</volume>
<page-range>715-22</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lohmeyer]]></surname>
<given-names><![CDATA[JA]]></given-names>
</name>
<name>
<surname><![CDATA[Essmann]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Richerson]]></surname>
<given-names><![CDATA[SJ]]></given-names>
</name>
<name>
<surname><![CDATA[Hagel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Egana]]></surname>
<given-names><![CDATA[JT]]></given-names>
</name>
<name>
<surname><![CDATA[Condurache]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Use of erythropoietin as adjuvant therapy in nerve reconstruction]]></article-title>
<source><![CDATA[Langenbecks Arch Surg.]]></source>
<year>2008</year>
<volume>393</volume>
<page-range>317-23</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Schmidt]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Ramos]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Silva]]></surname>
<given-names><![CDATA[JEP]]></given-names>
</name>
<name>
<surname><![CDATA[Fronza]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Dalmora]]></surname>
<given-names><![CDATA[SL]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Avaliação da atividade e caracterização de eritropoietina humana recombinante em produtos farmacêuticos]]></article-title>
<source><![CDATA[Arq Bras Endocrinol Metab.]]></source>
<year>2003</year>
<volume>47</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>183-9</page-range></nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bento]]></surname>
<given-names><![CDATA[RMA]]></given-names>
</name>
<name>
<surname><![CDATA[Damasceno]]></surname>
<given-names><![CDATA[LMP]]></given-names>
</name>
<name>
<surname><![CDATA[Neto]]></surname>
<given-names><![CDATA[FRA]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Eritropoetina humana recombinante no esporte: uma revisão]]></article-title>
<source><![CDATA[Rev Bras Med Esporte]]></source>
<year>2003</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>169-80</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Bahlmann]]></surname>
<given-names><![CDATA[FH]]></given-names>
</name>
<name>
<surname><![CDATA[Fliser]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin and renoprotection]]></article-title>
<source><![CDATA[Hypertension]]></source>
<year>2009</year>
<volume>18</volume>
<page-range>15-20</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Engert]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recombinant human erythropoietin in oncology: Current statuts and further developments]]></article-title>
<source><![CDATA[Ann Oncol.]]></source>
<year>2005</year>
<volume>16</volume>
<page-range>1584-95</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hardee]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Arcasoy]]></surname>
<given-names><![CDATA[MO]]></given-names>
</name>
<name>
<surname><![CDATA[Blackwell]]></surname>
<given-names><![CDATA[KL]]></given-names>
</name>
<name>
<surname><![CDATA[Kirkpatrick]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
<name>
<surname><![CDATA[Dewhirst]]></surname>
<given-names><![CDATA[MW]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin biology in cancer]]></article-title>
<source><![CDATA[Clin Cancer Res.]]></source>
<year>2006</year>
<volume>12</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>332-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hsieh]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Linde]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Wynter]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Metzger]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Wong]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Langsetmo]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[HIF prolyl hydroxylase inhibition results in endogenous erythropoietin induction, erythrocytosis, and modest fetal hemoglobin expression in rhesus macaques]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2007</year>
<volume>110</volume>
<page-range>2140-7</page-range></nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jelkmann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Pagel]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Wolff]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Fandrey]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Monokines inhibiting erythropoietin production in human hepatoma cultures and in isolated perfused rat kidneys]]></article-title>
<source><![CDATA[Life Sci.]]></source>
<year>1992</year>
<volume>50</volume>
<page-range>301-8</page-range></nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tentori]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Graziani]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Doping with growth hormone/IGF-1, anabolic steroids or erythropoietin: Is there a cancer risk?]]></article-title>
<source><![CDATA[Pharmacol Res.]]></source>
<year>2007</year>
<volume>55</volume>
<page-range>359-69</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ng]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Marx]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Littlewood]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Macdougall]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recombinant erythropoietin in clinical practice]]></article-title>
<source><![CDATA[Postgrad Med J.]]></source>
<year>2003</year>
<volume>79</volume>
<page-range>367-76</page-range></nlm-citation>
</ref>
<ref id="B31">
<label>31</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robach]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Schmitt]]></surname>
<given-names><![CDATA[EL]]></given-names>
</name>
<name>
<surname><![CDATA[Brugniaux]]></surname>
<given-names><![CDATA[JV]]></given-names>
</name>
<name>
<surname><![CDATA[Nicolet]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Duvallet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Fouillot]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Living high-training low: Effect on erythropoiesis and maximal aerobic performance in elite Nordic skiers]]></article-title>
<source><![CDATA[Eur J Appl Physiol.]]></source>
<year>2006</year>
<volume>97</volume>
<page-range>695-705</page-range></nlm-citation>
</ref>
<ref id="B32">
<label>32</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsitsimpikou]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Kouretas]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Tsarouhas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Fitch]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Spandidos]]></surname>
<given-names><![CDATA[DA]]></given-names>
</name>
<name>
<surname><![CDATA[Tsatsakis]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Applications and biomonitoring issues of recombinant erythropoietins for doping control]]></article-title>
<source><![CDATA[Ther Drug Monit.]]></source>
<year>2011</year>
<volume>33</volume>
<page-range>3-13</page-range></nlm-citation>
</ref>
<ref id="B33">
<label>33</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jelkmann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin: Structure, control of production and function]]></article-title>
<source><![CDATA[Physiol Rev.]]></source>
<year>1992</year>
<volume>72</volume>
<page-range>449-89</page-range></nlm-citation>
</ref>
<ref id="B34">
<label>34</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Inoue]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Takeuchi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ohashi]]></surname>
<given-names><![CDATA[H]]></given-names>
</name>
<name>
<surname><![CDATA[Suzuki]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The production of recombinant human erythropoietin]]></article-title>
<source><![CDATA[Biotechnol Annu Rev.]]></source>
<year>1995</year>
<volume>1</volume>
<page-range>297-313</page-range></nlm-citation>
</ref>
<ref id="B35">
<label>35</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Skibeli]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen-Lie]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Torjesen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Sugar profiling proves that human serum erythropoietin differs from recombinant human erythropoietin]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2001</year>
<volume>98</volume>
<page-range>3626-34</page-range></nlm-citation>
</ref>
<ref id="B36">
<label>36</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Storring]]></surname>
<given-names><![CDATA[PL]]></given-names>
</name>
<name>
<surname><![CDATA[Tiplady]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Gaines Das]]></surname>
<given-names><![CDATA[RE]]></given-names>
</name>
<name>
<surname><![CDATA[Stenning]]></surname>
<given-names><![CDATA[BE]]></given-names>
</name>
<name>
<surname><![CDATA[Lamikanra]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Rafferty]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Epoetin alfa and beta differ in their erythropoietin isoform compositions and biological properties]]></article-title>
<source><![CDATA[Br J Haematol.]]></source>
<year>1998</year>
<volume>100</volume>
<page-range>79-89</page-range></nlm-citation>
</ref>
<ref id="B37">
<label>37</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Macdougall]]></surname>
<given-names><![CDATA[IC]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Meeting the challenges of a new millennium: Optimizing the use of recombinant human erythropoietin]]></article-title>
<source><![CDATA[Nephrol Dial Transplant.]]></source>
<year>1998</year>
<volume>13</volume>
<page-range>23-7</page-range></nlm-citation>
</ref>
<ref id="B38">
<label>38</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Sackmann-Sala]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz-Topete]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Jorgensen]]></surname>
<given-names><![CDATA[JO]]></given-names>
</name>
<name>
<surname><![CDATA[Jessen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lundby]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Novel serum biomarkers for erythropoietin use in humans: A proteomic approach]]></article-title>
<source><![CDATA[J Appl Physiol.]]></source>
<year>2011</year>
<volume>110</volume>
<page-range>149-56</page-range></nlm-citation>
</ref>
<ref id="B39">
<label>39</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kohler]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Ayotte]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Desharnais]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Flenker]]></surname>
<given-names><![CDATA[U]]></given-names>
</name>
<name>
<surname><![CDATA[Lüdke]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Thevis]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Discrimination of recombinant and endogenous urinary erythropoietin by calculating relative mobility values from SDS gels]]></article-title>
<source><![CDATA[Int J Sports Med.]]></source>
<year>2008</year>
<volume>29</volume>
<page-range>1-6</page-range></nlm-citation>
</ref>
<ref id="B40">
<label>40</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Abellan]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Ventura]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Pichini]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Palmi]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Bellver]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Olive]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effect of physical fitness and endurance exercise on indirect biomarkers of recombinant erythropoietin misuse]]></article-title>
<source><![CDATA[Int J Sports Med.]]></source>
<year>2007</year>
<volume>28</volume>
<page-range>9-15</page-range></nlm-citation>
</ref>
<ref id="B41">
<label>41</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Giraud]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Saudan]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Baume]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Avois]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Mangin]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin and blood doping]]></article-title>
<source><![CDATA[Br J Sports Med.]]></source>
<year>2006</year>
<volume>40</volume>
<page-range>30-4</page-range></nlm-citation>
</ref>
<ref id="B42">
<label>42</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lundby]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Achman-Andersen]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Norgaard]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Robach]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Testing for recombinant human erythropoietin in urine: Problems associated with current anti-doping testing]]></article-title>
<source><![CDATA[J Appl Physiol.]]></source>
<year>2008</year>
<volume>105</volume>
<page-range>417-9</page-range></nlm-citation>
</ref>
<ref id="B43">
<label>43</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lamon]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Robinson]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Saugy]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Procedures for monitoring recombinant erythropoietin and analogs in doping]]></article-title>
<source><![CDATA[Endocrinol Metab Clin N Am.]]></source>
<year>2010</year>
<volume>39</volume>
<page-range>141-54</page-range></nlm-citation>
</ref>
<ref id="B44">
<label>44</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsivou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Georgakopoulos]]></surname>
<given-names><![CDATA[DG]]></given-names>
</name>
<name>
<surname><![CDATA[Dimopoulou]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
<name>
<surname><![CDATA[Koupparis]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Atta-Politou]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Georgakopoulos]]></surname>
<given-names><![CDATA[CG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Stabilization of human urine abuse in sports: The antidoping perspective]]></article-title>
<source><![CDATA[Asian J Androl.]]></source>
<year>2008</year>
<volume>10</volume>
<page-range>391-402</page-range></nlm-citation>
</ref>
<ref id="B45">
<label>45</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[John]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Jaison]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Jain]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Kakkar]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Jacob]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin use and abuse]]></article-title>
<source><![CDATA[Indian J Endocrinol Metab.]]></source>
<year>2012</year>
<volume>16</volume>
<page-range>220-7</page-range></nlm-citation>
</ref>
<ref id="B46">
<label>46</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Robach]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Recalcati]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Girelli]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Gelfi]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Aachmann-Andersen]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Alterations of systemic and muscle iron metabolism in human subjects treated with low-dose recombinant erythropoietin]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2009</year>
<volume>113</volume>
<numero>26</numero>
<issue>26</issue>
<page-range>6707-15</page-range></nlm-citation>
</ref>
<ref id="B47">
<label>47</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ashenden]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Clare]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Gough]]></surname>
<given-names><![CDATA[CE]]></given-names>
</name>
<name>
<surname><![CDATA[Garnham]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gore]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Sharpe]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Current markers of the Athlete Blood Passport do not flag microdose EPO doping]]></article-title>
<source><![CDATA[Eur J Appl Physiol.]]></source>
<year>2011</year>
<volume>111</volume>
<page-range>2307-14</page-range></nlm-citation>
</ref>
<ref id="B48">
<label>48</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lundby]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Robach]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Assessment of total haemoglobin mass: Can it detect erythropoietin-induced blood manipulations?]]></article-title>
<source><![CDATA[Eur J Appl Physiol.]]></source>
<year>2010</year>
<volume>108</volume>
<page-range>197-200</page-range></nlm-citation>
</ref>
<ref id="B49">
<label>49</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ninot]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Connes]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Caillaud]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of recombinant human erythropoietin injections on physical self in endurance athletes]]></article-title>
<source><![CDATA[J Sports Sci.]]></source>
<year>2006</year>
<volume>24</volume>
<page-range>383-91</page-range></nlm-citation>
</ref>
<ref id="B50">
<label>50</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Verbrugge]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Goodnough]]></surname>
<given-names><![CDATA[LT]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[The effect of recombinant human erythropoietin treatment on the endurance performance of Sprague-Dawley rats]]></article-title>
<source><![CDATA[Scand J Clin Lab Invest.]]></source>
<year>1994</year>
<volume>54</volume>
<page-range>55-9</page-range></nlm-citation>
</ref>
<ref id="B51">
<label>51</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kiss]]></surname>
<given-names><![CDATA[MAPDM]]></given-names>
</name>
<name>
<surname><![CDATA[Böhme]]></surname>
<given-names><![CDATA[MTS]]></given-names>
</name>
<name>
<surname><![CDATA[Mansoldo]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Degaki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Regazzini]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Desempenho e talento esportivos]]></article-title>
<source><![CDATA[Rev Paul Educ Fís.]]></source>
<year>2004</year>
<volume>18</volume>
<page-range>89-100</page-range></nlm-citation>
</ref>
<ref id="B52">
<label>52</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jelkmann]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Lundby]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Blood doping and its detection]]></article-title>
<source><![CDATA[Blood]]></source>
<year>2011</year>
<volume>118</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>2395-404</page-range></nlm-citation>
</ref>
<ref id="B53">
<label>53</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Russell]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gore]]></surname>
<given-names><![CDATA[CJ]]></given-names>
</name>
<name>
<surname><![CDATA[Ashenden]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Parisotto]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Hahn]]></surname>
<given-names><![CDATA[AG]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of prolonged low doses of recombinant human erythropoietin during submaximal and maximal exercise]]></article-title>
<source><![CDATA[Eur J Appl Physiol.]]></source>
<year>2002</year>
<volume>86</volume>
<page-range>442-9</page-range></nlm-citation>
</ref>
<ref id="B54">
<label>54</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lundby]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Robach]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Boushel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Koskolou]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Does recombinant human Epo increase exercise capacity by means other than augmenting oxygen transport?]]></article-title>
<source><![CDATA[J Appl Physiol.]]></source>
<year>2008</year>
<volume>105</volume>
<page-range>581-7</page-range></nlm-citation>
</ref>
<ref id="B55">
<label>55</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rentsch]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Robach]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Calbet]]></surname>
<given-names><![CDATA[JAL]]></given-names>
</name>
<name>
<surname><![CDATA[Boushel]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Prolonged administration of recombinant human erythropoietin increases submaximal performance more than maximal aerobic capacity]]></article-title>
<source><![CDATA[Eur J Appl Physiol.]]></source>
<year>2007</year>
<volume>101</volume>
<page-range>481-6</page-range></nlm-citation>
</ref>
<ref id="B56">
<label>56</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wilkerson]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Rittweger]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Berger]]></surname>
<given-names><![CDATA[NJ]]></given-names>
</name>
<name>
<surname><![CDATA[Naish]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Influence of recombinant human erythropoietin treatment on pulmonary O2 uptake kinetics during exercise in humans]]></article-title>
<source><![CDATA[J Physiol.]]></source>
<year>2005</year>
<volume>15</volume>
<page-range>639-52</page-range></nlm-citation>
</ref>
<ref id="B57">
<label>57</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Durussel]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Daskalaki]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Anderson]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Chatterji]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Wondimu]]></surname>
<given-names><![CDATA[DH]]></given-names>
</name>
<name>
<surname><![CDATA[Padmanabhan]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Haemoglobin mass and running time trial performance after recombinant human erythropoietin administration in trained men]]></article-title>
<source><![CDATA[PLoS One]]></source>
<year>2013</year>
<volume>8</volume>
<numero>2</numero>
<issue>2</issue>
</nlm-citation>
</ref>
<ref id="B58">
<label>58</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zagatto]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Papoti]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Caputo]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Mendes]]></surname>
<given-names><![CDATA[OC]]></given-names>
</name>
<name>
<surname><![CDATA[Denadai]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
<name>
<surname><![CDATA[Baldissera]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Comparação entre a utilização de saliva e sangue para determinação do lactato mínimo em cicloergômetro e ergômetro de braço em mesa-tenistas]]></article-title>
<source><![CDATA[Rev Bras Med Esporte]]></source>
<year>2004</year>
<volume>10</volume>
<page-range>475-80</page-range></nlm-citation>
</ref>
<ref id="B59">
<label>59</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Freitas]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
<name>
<surname><![CDATA[Junior]]></surname>
<given-names><![CDATA[MAC]]></given-names>
</name>
<name>
<surname><![CDATA[Franco]]></surname>
<given-names><![CDATA[FSC]]></given-names>
</name>
<name>
<surname><![CDATA[Rezende]]></surname>
<given-names><![CDATA[LS]]></given-names>
</name>
<name>
<surname><![CDATA[Santos]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Maia]]></surname>
<given-names><![CDATA[HO]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Treinamento aeróbio em natação melhora a resposta de parâmetros metabólicos de ratos durante teste de esforço]]></article-title>
<source><![CDATA[Rev Bras Med Esporte]]></source>
<year>2010</year>
<volume>16</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>134-8</page-range></nlm-citation>
</ref>
<ref id="B60">
<label>60</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cayla]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
<name>
<surname><![CDATA[Maire]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Duvallet]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Wahrmann]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin induces a shift of muscle phenotype from fast glycolytic to slow oxidative]]></article-title>
<source><![CDATA[Int J Sports Med.]]></source>
<year>2008</year>
<volume>296</volume>
<page-range>460-5</page-range></nlm-citation>
</ref>
<ref id="B61">
<label>61</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rasmussen]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Foged]]></surname>
<given-names><![CDATA[EM]]></given-names>
</name>
<name>
<surname><![CDATA[Krogh-Madsen]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Nielsen]]></surname>
<given-names><![CDATA[TR]]></given-names>
</name>
<name>
<surname><![CDATA[Olsen]]></surname>
<given-names><![CDATA[NV]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of erythropoietin administration on cerebral metabolism and exercise capacity in men]]></article-title>
<source><![CDATA[J Appl Physiol.]]></source>
<year>2010</year>
<volume>109</volume>
<page-range>476-83</page-range></nlm-citation>
</ref>
<ref id="B62">
<label>62</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Katz]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Stuible]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Golishevski]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Lifshitz]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Tremblay]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Gassmann]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin treatment leads to reduced blood glucose levels and body mass: Insights from murine models]]></article-title>
<source><![CDATA[J Endocrinol.]]></source>
<year>2010</year>
<volume>205</volume>
<page-range>87-95</page-range></nlm-citation>
</ref>
<ref id="B63">
<label>63</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mikolás]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Cseh]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[PAP]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Szijarto]]></surname>
<given-names><![CDATA[IA]]></given-names>
</name>
<name>
<surname><![CDATA[Balogh]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Laczy]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of erythropoietin on glucose metabolism]]></article-title>
<source><![CDATA[Horm Metab Res.]]></source>
<year>2012</year>
<volume>44</volume>
<page-range>279-85</page-range></nlm-citation>
</ref>
<ref id="B64">
<label>64</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Christensen]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Vendelbo]]></surname>
<given-names><![CDATA[MH]]></given-names>
</name>
<name>
<surname><![CDATA[Krusenstjerna-Hafstrom]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Madsen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Pedersen]]></surname>
<given-names><![CDATA[SB]]></given-names>
</name>
<name>
<surname><![CDATA[Jessen]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin administration acutely stimulates resting energy expenditure in healthy young men]]></article-title>
<source><![CDATA[J Appl Physiol.]]></source>
<year>2012</year>
<volume>112</volume>
<page-range>1114-21</page-range></nlm-citation>
</ref>
<ref id="B65">
<label>65</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lin]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
<name>
<surname><![CDATA[Qu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Hu]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jiang]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Protective effect of erythropoietin on renal injury induced by acute exhaustive exercise in the rat]]></article-title>
<source><![CDATA[Int J Sports Med.]]></source>
<year>2010</year>
<volume>31</volume>
<page-range>847-53</page-range></nlm-citation>
</ref>
<ref id="B66">
<label>66</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Lodewijkx]]></surname>
<given-names><![CDATA[HF]]></given-names>
</name>
<name>
<surname><![CDATA[Brouwer]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Some empirical notes on the epo epidemic in professional cycling]]></article-title>
<source><![CDATA[Res Q Exerc Sport]]></source>
<year>2011</year>
<volume>82</volume>
<page-range>740-54</page-range></nlm-citation>
</ref>
<ref id="B67">
<label>67</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Juel]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
<name>
<surname><![CDATA[Thomsen]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Rentsch]]></surname>
<given-names><![CDATA[RL]]></given-names>
</name>
<name>
<surname><![CDATA[Lundby]]></surname>
<given-names><![CDATA[C]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Effects of prolonged recombinant human erythropoietin administration on muscle membrane transport systems and metabolic marker enzymes]]></article-title>
<source><![CDATA[Eur J Appl Physiol.]]></source>
<year>2007</year>
<volume>102</volume>
<page-range>41-4</page-range></nlm-citation>
</ref>
<ref id="B68">
<label>68</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Martinez-Bello]]></surname>
<given-names><![CDATA[VE]]></given-names>
</name>
<name>
<surname><![CDATA[Sanchis-Gomar]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Romagnoli]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Derbre]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Gomez-Cabrera]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Vina]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Three weeks of erythropoietin treatment hampers skeletal muscle mitochondrial biogenesis in rats]]></article-title>
<source><![CDATA[J Physiol Biochem.]]></source>
<year>2012</year>
<volume>68</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>593-601</page-range></nlm-citation>
</ref>
<ref id="B69">
<label>69</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Eagleton]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Littlewood]]></surname>
<given-names><![CDATA[TJ]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Update on the clinical use and misuse of erythropoietin]]></article-title>
<source><![CDATA[Curr Hematol Rep.]]></source>
<year>2003</year>
<volume>2</volume>
<page-range>109-15</page-range></nlm-citation>
</ref>
<ref id="B70">
<label>70</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Piloto]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Teixeira]]></surname>
<given-names><![CDATA[HM]]></given-names>
</name>
<name>
<surname><![CDATA[Teixeira-Lemos]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Parada]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
<name>
<surname><![CDATA[Garrido]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Sereno]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin promotes deleterious cardiovascular effects and mortality risk in a rat model of chronic]]></article-title>
<source><![CDATA[Cardiovasc Toxicol.]]></source>
<year>2009</year>
<volume>9</volume>
<page-range>201-10</page-range></nlm-citation>
</ref>
<ref id="B71">
<label>71</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[TS]]></given-names>
</name>
<name>
<surname><![CDATA[Cunha]]></surname>
<given-names><![CDATA[NS]]></given-names>
</name>
<name>
<surname><![CDATA[Moura]]></surname>
<given-names><![CDATA[MJCS]]></given-names>
</name>
<name>
<surname><![CDATA[Marcondes]]></surname>
<given-names><![CDATA[FK]]></given-names>
</name>
</person-group>
<article-title xml:lang="pt"><![CDATA[Esteróides anabólicos androgênicos e sua relação com a prática desportiva]]></article-title>
<source><![CDATA[Braz J Pharm Sci.]]></source>
<year>2004</year>
<volume>40</volume>
<page-range>165-79</page-range></nlm-citation>
</ref>
<ref id="B72">
<label>72</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jones]]></surname>
<given-names><![CDATA[EH]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Recombinant human erythropoietin]]></article-title>
<source><![CDATA[Am J Hosp Pharm.]]></source>
<year>1989</year>
<volume>46</volume>
<page-range>20-3</page-range></nlm-citation>
</ref>
<ref id="B73">
<label>73</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Meziri]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Binda]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Touati]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Pellegrin]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Berthelot]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Touyz]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Exercise aggravates cardiovascular risks and mortality in rats with disrupted nitric oxide pathway and treated with recombinant human erythropoietin]]></article-title>
<source><![CDATA[Eur J Physiol.]]></source>
<year>2011</year>
<volume>111</volume>
<page-range>1929-38</page-range></nlm-citation>
</ref>
<ref id="B74">
<label>74</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Guglin]]></surname>
<given-names><![CDATA[ME]]></given-names>
</name>
<name>
<surname><![CDATA[Koul]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Cardiovascular effects of erythropoietin: anemia and beyond]]></article-title>
<source><![CDATA[Cardiol Rev.]]></source>
<year>2006</year>
<volume>14</volume>
<page-range>200-4</page-range></nlm-citation>
</ref>
<ref id="B75">
<label>75</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Manolis]]></surname>
<given-names><![CDATA[AS]]></given-names>
</name>
<name>
<surname><![CDATA[Tzeis]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Triantafyllou]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Michaelidis]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Pyrros]]></surname>
<given-names><![CDATA[I]]></given-names>
</name>
<name>
<surname><![CDATA[Sakellaris]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang="en"><![CDATA[Erythropoietin in heart failure and other cardiovascular diseases: Hematopoietic and pleiotropic effects]]></article-title>
<source><![CDATA[Curr Drug Targets Cardiovasc Haematol Disord.]]></source>
<year>2005</year>
<volume>5</volume>
<page-range>355-75</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
